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ABSTRACT

PART I: AN INVESTIGATION OF CALCITROIC ACID AND ITS PHASE II CONJUGATES
by
Olivia B. Yu
The University of Wisconsin-Milwaukee, 2019
Under the Supervision of Professor Alexander Arnold

Calcitroic acid (CTA) was isolated and characterized more than four decades ago.5
Radiolabeled calcitriol (1,25-dihydroxyvitamin D3) was used at that time to enable the
identification of radioactive CTA formed in vivo, which was subsequently extracted and
characterized by derivatization.7 CTA was found to be predominantly formed in the liver and
secreted into the gut through the bile duct via enterohepatic circulation, leading to fairly high
concentrations of this metabolite of vitamin D in the intestine.8 However, assuming it was only a
catabolic product of calcitriol, it was ignored thereafter.
Recently, novel experiments showed that CTA can bind the vitamin D receptor (VDR) and
initiate gene regulation of certain metabolic enzymes.4 The VDR is a nuclear hormone receptor
and is present in many tissues.9 VDR is a biological sensor with the ability to bind several
endogenous ligands. Calcitriol has the highest known affinity for VDR and has been very
thoroughly investigated. In contrast to that, very little is known about the main final metabolite
of vitamin D: calcitroic acid. Because its binding to VDR is weaker than calcitriol, it was presumed
to be biologically inactive at the time of its discovery.
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Gene regulation in the presence of CTA has now been demonstrated in epithelia,
keratinocytes, and prostate cancer cells.8 One assumed function of VDR in the intestine is the
regulation of P450 enzymes. These are important enzymes for detoxification, especially with
respect to harmful accumulation of toxic endogenous small molecules, such as lithocholic acid.
Our hypothesis is that CTA regulates this process in conjunction with VDR for the purpose of
preventing the development of inflammation-based gastrointestinal diseases such as irritable
bowel syndrome, or even colorectal cancer.
My research has been focused on producing CTA synthetically and testing its effects in
vitro and in vivo. Due to it being unavailable for purchase at a reasonable price and the difficulty
of its synthesis, much of my research was focused on modifying and optimizing a lengthy
synthetic route to the final product. Secondarily, I generated 13C-labeled CTA to be used as an
isotopic standard to enable the quantification of CTA in bodily fluids. Several proposed phase
two conjugates of CTA and the recently discovered other final vitamin D metabolite calcioic acid
were also synthesized following novel synthetic routes. We confirmed the binding between
these analogs and VDR. The availability of CTA conjugates will support their quantification in vivo
in future studies using LCMS/MS and MALDI-TOF/TOF. Additionally, VDR’s expression in
leukocytes has shown immune suppression influence with calcitriol as its ligand. Studies with CTA
and its conjugates also have indicated similar anti-inflammatory effects. Further studies will be
conducted to determine whether CTA or its conjugates have any of the suspected detoxification
properties in the gut.
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ABSTRACT

PART II: TOWARD THE DEVELOPMENT OF A NOVEL ORALLY-AVAILABLE ASTHMA
TREATMENT TARGETING GABAA RECEPTORS IN THE LUNGS
by
Olivia B. Yu
The University of Wisconsin-Milwaukee, 2019
Under the Supervision of Professor Alexander Arnold

The treatment and control of asthma remains a persistent modern clinical problem,
despite being recognized for decades and occurrence across the globe.10 The central hallmarks
of asthma are chronically inflamed airways, hypersensitivity to certain external stimuli, and
obstruction of the airways.11 These characteristics lead to clinical features that include persistent
cough, shortness of breath, wheezing, coughing, and chest tightness.12
Our laboratory, in collaboration with the Cook laboratory at UWM, is seeking an alternate
therapy to combat multiple symptoms associated with living with acute asthma.1, 13 Currently
available treatments have multiple factors that could be improved upon, from the imprecise
dosages of treatment delivered via inhaler14 to the adverse side effects of systemically
administered corticosteroids.15-19 A better asthma drug alternative would be orally administered
to improve patient compliance and eliminate dosage irregularity. Furthermore, unwanted
central nervous system effects should be avoided at all cost. Finally, the alternative drug should
alleviate a full range of asthma symptoms, such as relaxing the smooth muscle constriction and
decreasing inflammation in the airways, rendering combination treatments obsolete.20
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Central to achieving those goals is a new therapeutic target for asthma, which is the
family of gamma-aminobutyric acid A receptors (GABAAR). GABAARs are ligand-gated chloride ion
channels, whose primary function is to regulate intracellular chloride concentrations, especially
in neurons. The GABAARs consists of five subunits combined into a heteropentamer.21 In recent
decades, the Cook group has introduced GABAAR ligands based on the imidazobenzodiazepine
scaffold that are selective to certain subtypes of GABAARs.22 With recent confirmation that
distinct populations of GABAAR subtypes are present in lung tissue, our collaboration is keen to
develop molecules that can target these subtypes. Further investigations have shown that these
ligands mediate distinct pharmacological properties including relaxation of airway smooth
muscle and anti-inflammation. Proof of concept that GABAAR ligands can alleviate asthma
symptoms was first shown with plant-based positive allosteric modulator honokiol by Munroe et
al.23 Our group has since developed imidazobenzodiazepine-based compounds that target
relevant GABAAR subtypes expressed in the lung with pronounced efficacy in several asthmatic
mouse models.1, 13, 20, 24 Achieving targeted asthmatic relief with oral medication and thus
eliminating the use of corticosteroids is seen as a significant step forward in asthma treatment.
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PART I: AN INVESTIGATION OF CALCITROIC ACID AND ITS PHASE II CONJUGATES

1

1.1 A Brief History of Vitamin D

The establishment of vitamins as essential to a complete diet is actually a surprisingly
new discovery, made after the turn of the twentieth century. While certain diseases caused by
vitamin-deficiency had already been discovered and were known to be treatable by
supplementing one’s diet,25 the reasons behind the supplemental cures were unknown or
incorrect at that time. The early 1900’s saw the discovery of the first few “vital amines,” or
vitamins, in large part due to the work of Elmer McCollum. Following the 1910 demonstrations
by both Hopkins26 and Funk27 that a diet consisting only of purified proteins, fats, salts, and
carbohydrates was incapable of encouraging animal growth, McCollum isolated a lipophilic nonsaponifiable compound from butter fat which was found to be necessary for growth and
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prevented xerophthalmia in rats in 1914.28 This “factor A” soon became known as vitamin A, and
its discovery led to vitamin B’s discovery by McCollum (amongst others)29 only four years later.30
At the same time, in the Industrial Revolution in England in the early twentieth century,
cases of rickets, especially in children, had reached epidemic proportions as polluted air blocked
the sun and people living in poverty worked long hours in factories.31 The discovery of the first
vitamins led to administration of cod liver oil, a good source of vitamin A, but which also
unbeknownst contained vitamins D and E as well. The treatment with cod liver oil cured rickets,
but McCollum, doubting whether it was in fact vitamin A’s action, performed a groundbreaking
study. He oxidized vitamin A in cod liver oil to destroy its activity, and found that even so it could
be used to cure rickets (though not the vitamin A deficiency disease xerophthalmia).32 He thus
concluded that there was another vital vitamin present in cod liver oil that cured rickets, and
called this vitamin D,33 as it was the fourth vitamin to be discovered and named.
In Europe, a discovery about curing rickets from a completely different source was made
by both Huldschinsky34 and Chick et al.35 They independently showed that rickets could also be
cured by exposing ricketic children to UV light. Therapeutic exposure to sunlight was no different
than cod liver oil administration in curing the disease, providing the interesting insight that
vitamin D has both vitamin-like and hormone-like properties.36 Steenbock, at Wisconsin,
confirmed this in 1924 when he showed that he could induce vitamin D activity to cure rickets in
lactating goats by irradiating both animals and diets with UV light. This showed that there was an
inactive substance present that could be converted to an active form of vitamin D.
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The isolation of vitamin D itself was initially in error, as Windaus in Germany accidentally first
found a tachysterol/ergocalciferol adduct that was active against rickets and called it vitamin
D1.37 Later, the true first isolation and structure determination of ergocalciferol (vitamin D2) was
successfully conducted by Askew in Britain,38 which Windaus’ group later confirmed.39 Windaus
and Bock went on in 1936 to isolate from skin 7-dehydrocholesterol, a precursor to vitamin D3,
and convert it to cholecalciferol.40-41 Thereby the two nutritional forms of vitamin D were
identified.
It was not until 1967 that Hector DeLuca showed that radiolabeled vitamin D was not in
fact the active form.42 Polar metabolites in target tissues caused the physiological response and
were far more biologically active than unmetabolized vitamin D. In 1968, his group isolated the
primary circulating form of vitamin D, the metabolite 25-hydroxyvitamin D3 (25(OH)D3), which
was temporarily thought to be its most active form.43 However, DeLuca’s group later
demonstrated indisputably that the yet more polar molecule 1,25-dihydroxyvitamin D3
(1,25(OH)2D3, trivial name calcitriol) was in fact the primary active form of vitamin D.44
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1.2 The Structure and Function of the Vitamin D Receptor

The vitamin D receptor (VDR) belongs to the superfamily of nuclear receptors and
functions as a transcription factor. The receptor is responsible for the regulations of genes
involved in calcium homeostasis, cell proliferation, and cell differentiation.45 While vitamin D was
rapidly isolated in 1930,46 it took the field nearly 40 years to begin to discover that the
metabolism of vitamin D was necessary to create biologically active molecules.42 This is due to
their interactions with VDR: while VDR binds vitamin D metabolites and other molecules, the
actual vitamin D2 and D3 molecules do not bind to the receptor.
VDR was identified in 197347 and cloned fourteen years later.48 In 2000, the first portion
of VDR’s three-dimensional structure was elucidated by X-ray crystallography: the ligand binding
domain (LBD), responsible for binding small molecules. The ligand binding domain consists of
6

three β-sheets and three layers of 12 α-helices in sandwich folds (Figure 1a). It undergoes a
major conformational change when a ligand is bound. Helix 11 shifts over and aligns with helix
10, which allows helix 12 (pink) to swing shut to the position shown in Figure 1a and close off the
binding pocket. Helix 12 is the “activating domain,” allowing the structure to stabilize by
contributing to additional contacts with the ligand and overall making a more hydrophobic
environment in the ligand pocket. Within the binding pocket, VDR’s native ligand calcitriol takes
up only 56% of the cavity (blue mesh in Figure 1b). R274 and S278 from Helix 5, S237 from Helix
3, Y143 from loop H1-H2, H305 from loop H6-H7, and H397 from Helix 11 form the anchoring
hydrogen bonds that hold 1,25(OH)2D3 in the binding cavity (see Figure 1).49
A

B

Figure 1: (a) The 12 α-helices of VDR represented as cylinders, with the activating domain helix shown in its closed position (pink)
and its native ligand bound (yellow ball-and-stick). (b) The binding pocket cavity (blue mesh) and the anchoring interactions with
surrounding residues that hold 1,25(OH)2D3 in the binding cavity.

To function as a transcription factor, VDR must in addition to binding small molecules
also interact with cofactors, bind to activating DNA sequences, and take part in its heterodimer
7

with the retinoid X receptor (RXR). It thus has more than one domain (Figure 2). The A/B domain
is at the N-terminus, and amongst nuclear receptors this domain is non-conserved as it is the
part that binds various cofactors and enzymes.50 In VDR, this domain contains activating function
1 (AF-1), which has some weak transcriptional activity in the absence of ligand.50
A/B
AF-1

A/B

C

D

C

DBD

E
LBD

D

F

AF-2

Figure 2: A schematic and crystal structure outlining the general domains of a nuclear
receptor. Structures adapted courtesy of the Protein Data Bank and Brzozowski AM, et.al.3

The C domain, also known as the DNA binding domain, is highly conserved across nuclear
receptors51 (Figure 3). It consists of 66 residues formed into two structures, both of which
contain zinc finger motifs. The amino-terminal zinc finger region binds to the major groove of

Figure 3: Crystal structure of the DBDs of both VDR (left) and its typical heterodimer partner
RXR (right) bound to their respective DNA hexameric half-sites.6 The light blue alpha helices
in both structures bind to the major groove of the DNA. The Zn2+ ions taking part in
coordination with cysteine residues are shown in gray. (PDB: 1YNW)
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DNA at certain sequences called hormone response elements. The second zinc finger region is
used to heterodimerize with other proteins.52-53 A typical hormone response element for the
VDR-RXR heterodimer contains two hexameric half-sites with the sequence 5’-AGGTCA-3’ in a
direct repeat with three neutral base pair spacers,54 compared to other half-site combinations
for various nuclear receptors which can also involve inverted, everted, and mirror repeats. VDR
response elements include those for many gene targets, such as CYP24A1, CYP3A4, SULT2A1,
ABCB1, CYP2B6, CDKN1A, SPP1, OC, and OPN genes along with a host of others.55
The D domain is simply the highly flexible hinge region that connects the DBD and the
ligand binding domain (LBD), which is located in the E domain. The E domain is well-conserved
and as the name implies is responsible for binding ligands. It consists of three β-sheets and 12 αhelices in three layers of sandwich folds. This domain also interacts with coregulators
(corepressors and coactivators) in a ligand dependent manner56 (Figure 4). When a ligand is

Figure 4: A crystal stucture of the LBD of VDR. Within the binding pocket resides the
calcitriol analogue VitIII 17-20Z (gray ball-and-stick). The short helical peptide in the upper
left is the NR2 box of coactivator peptide DRIP 205 complexed to the LBD by way of the
coactivator recognition sequence LxxLL. (PDB: 204J)
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bound, a major conformational change occurs wherein Helix 12 swings shut over the binding
pocket, stabilizing the structure through additional contacts with the ligand and creating a more
hydrophobic environment in the binding pocket. Once helix 12 is in place, it provides a new
exterior surface with a hydrophobic cleft and the two charged residues K246 and E420 on either
end, forming a “charge clamp” with which coregulators and heterodimers interact.57
This ability to regulate activity based on the presence of ligands, coactivators, and
corepressors is known as the activating function 2 (AF-2) of the nuclear receptor: ligand
dependent activity, as opposed to the ligand-independent activity of AF-1. The ligand-binding
domain is thus the control center of VDR, regulating both DNA binding and transcription
modification.58 Within the LBD is the essential ligand “cave” known as the activating function 2

Figure 5: The flash-frozen RXR-VDR structure in complex with a DNA response element, as imaged by electron
microscopy and overlaid with individual crystal structures.2 A) Side view shows the ligand binding domains of VDR
(orange, facing) and RXR (green, far side) at ~90° angle from where they are bound to DNA. B) The DBDs encapsulate
the response element DNA, the two recognition helices positioned at about 45° from each other due to the 3 base-pair
spacer between the half-sites. Helix 12 is shown on VDR in red, in its closed position with ligands bound (shown in yellow
for VDR; blue for RXR).
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(AF-2) wherein binding with VDR’s many ligands occurs. Once a ligand has bound, AF-2 also
completes the interface for binding with the retinoid X receptor as well as other coactivators and
corepressors (Figure 5). When heterodimerized with the retinoid X receptor (VDR’s most
common dimeric partner), the two bind sequences on DNA known as “vitamin D-responsive
elements” (VDRE) on VDR target genes and recruit additional coactivators.59
The specificity of the target binding sequences allows for promoter-selective gene
transcription, and ultimately determines the rate of protein production via RNA polymerase II
transcription. Once the VDR-RXR heterodimer is bound, additional coactivators are recruited
including the RNA polymerase II and other transcriptional proteins with histone acetyl
transferases activity to mediate priming and eventual transcription of DNA.60
The F domain, which is entirely variable across nuclear receptors, is absent in VDR.61-62
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1.3 The Phase I Metabolism of Vitamin D and Calcitroic Acid

As noted previously, it took some time before scientists determined that it was not
vitamin D2 or D3 that acted on the vitamin D receptor, but instead its metabolites. This work was
pioneered in 1961 by Kodicek and Chalk with in vivo dosing of 14C-labeled vitamin D2 which
showed that metabolism of
the labeled vitamin was
occurring.63 However, it
was the administration of
3H-labeled

vitamin analogs

in the 1960s that led to the
first identification of a

Figure 6: To identify metabolic products from 1,25(OH)2D3, the 14C and 3H analogues
were administered. The resulting organ extracts contained an enriched 3H-labeled
material, indicating modification to the side chain in calcitriol’s metabolites.
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vitamin D analog with significant biological activity, 25(OH)D3.43 The same group also discovered
the most active vitamin D analog known, 1,25(OH)2D3, in 1971.64 These discoveries initiated
many research programs in the ﬁelds of medicine, biochemistry, physiology, chemistry, and
pharmacology, especially once the vitamin D receptor was identiﬁed65 and eventually cloned.48
A near miss to uncovering CTA occurred in 1965, when it was observed that signiﬁcant
radioactivity was present in the aqueous extracts of the bile and intestines of 1α-3H-D3 dosed
rats; however, none of these radioactive species were analyzed further.66 With improvement in
rat bile duct cannulation, the same group collected bile for 24 hours and separated it
chromatographically into ﬁve fractions including “fraction D,” which after acid hydrolysis
separated into polar and less polar fractions.67 A glucuronide conjugate of a vitamin D analog
was identiﬁed as a major component, which masked CTA; however, separation methods for
acidic metabolites such an anion-exchange chromatography and derivatization with
diazomethane were established. Although researchers repeatedly reported large amounts of
radioactivity for aqueous extracts of liver and intestine from 3H-25(OH)D3 treated animals,68 it
would take another 10 years until the ﬁrst isolation of CTA took place.7 In their study, rats were
treated with a combination of 14C- and 3H- labeled 1,25(OH)2D3 (Figure 6) and after 4 hours,
soluble contents of liver and intestine (with contents) were separated as a chloroform fraction
and methanol/water fraction. The aqueous layers of both tissues were enriched in 3H over 14C,
indicating that the side chain of 1,25(OH)2D3 was shortened during metabolism—a key finding.
Fractions of negatively charged compounds after diethylaminoethyl cellulose separation (anion
exchange) had especially signiﬁcant amounts of radioactivity. 3H-CTA was then isolated as methyl
14

ester after esteriﬁcation with diazomethane and characterized by mass spectrometry.7 Blood
was found to contain a small amount of 3H-CTA; however, much larger amounts were found in
the liver and especially in the intestine plus content. Thus, the hypothesis that CTA is part of the
enterohepatic circulation was subsequently conﬁrmed with the identiﬁcation of 3H-CTA in the
bile duct.8 A more detailed analysis of tissue distribution of CTA with the techniques stated
above using bolus administration of 1,25(OH)2-[3α-3H]D3 demonstrated a more complex
metabolism.69 Primarily, other acidic metabolites were found that were suggested to be polar
CTA conjugates, and secondarily, CTA was found in the intestine of bile duct-cannulated rats,
which suggests endogenous mucosal synthesis of CTA. In addition, only up to 50% of the
radioactive material could be extracted from dried liver, another indication of complex
metabolite formation.

Scheme 1: The metabolism of various vitamin D metabolites and analogues to CTA.
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Due to the attention that the organ chloroform extracts received, however, several less
abundant metabolites were identified long before CTA, uncovering one of the most pronounced
pathways for vitamin D metabolism. The ﬁrst evidence of the 24-hydroxylation of vitamin D was
found in the blood of [1,2-3H]D3-treated chicks, with the product initially believed to be
21,25(OH)2D3,70 but later identiﬁed as 24,25(OH)2D3 in chick kidney homogenates.71 It was
further discovered that 1,25(OH)2D3 increases the production of 24,25(OH)2D3, suggesting for
the ﬁrst time an upregulation of 24-hydoxylase (CYP24A1) by 1,25(OH)2D3.72 CYP24A1 was ﬁrst
identiﬁed in chick kidneys,73 and further characterization of the puriﬁed enzyme found in kidney
mitochondria was accomplished by several groups74-75 and eventually led to cloning and
expression of mitochondrial kidney CYP24A1.76
In the meantime, several new vitamin D metabolites were identiﬁed in vivo or with
perfused rat kidney: 24,25,26,27-tetranor-23(OH)D377 and 24,25,26,27-tetranor-1,23(OH)2D3,78
which were assumed to be the most likely precursors for CTA (Scheme 1). The conversion of
24,25,26,27-tetranor-1,23(OH)2D3 into CTA was then reported by two groups in the same year
using perfused rat kidney.79-80 It had already been shown that cultured bone cells mediated the
same metabolism in addition to the earlier reported conversion of 25-(OH)D3 to 24,25(OH)2D3.81
As such, it was known that the expression of CYP24A1 was not limited to the kidney. Analysis of
recombinant human CYP24A1 conﬁrmed that a single P450 enzyme catalyzed the six-step
pathway from 1,25(OH)2D3 to CTA,82 confirming the most pronounced CTA-generating route, the
C-24 hydroxylation pathway. In addition, it was demonstrated that CYP24A1 also mediated the
alternative C-23 hydroxylation pathway, a four-step monooxygenation from 25-(OH)D3 to
16

25(OH)D3-26,23-lactone, which interestingly was not observed for rat CYP24A1.83 Human
recombinant CYP24A1 was also able to catalyze the conversion of 25(OH)D3 to 24,25,26,27tetranor-23(OH)D3;84 however complete oxidation to calcioic acid was only observed in perfused
rat kidney.85 In addition, CTA was found in perfused kidney when treated with supplementderived 1,25(OH)2D2,86 although CYP24A1 seemed not to be the only enzyme involved in this
process.87 CTA was also identiﬁed in the bile of rats treated with 1,25(OH)2D4.88
Vitamin D analogs bearing an α1 hydroxyl functionality, such as 1,25(OH)2D3, bind more
strongly to VDR compared to their non-1α-hydroxylated counterpart (such as 25(OH)D3) and are
therefore biologically more active at the same concentration. The identiﬁcation, puriﬁcation, and
characterization of the responsible enzyme, 25-hydroxyvitamin D3 1α-hydroxylase (CYP27B1),
has been ongoing for ﬁve decades.89 Just as with CYP24A1, CYP27B1 expression is not limited to
kidney mitochondria. Only recently was it shown that CYP27B1 is able to convert most vitamin D
metabolites of the 24-hydroxylation pathway to their corresponding 1α-hydroxyl products;
however, the conversion of 24,25,26,27-tetranor-23(OH)D3 to 24,25,26,27-tetranor-1,23(OH)2D3
and calcioic acid to CTA have not been investigated yet.90
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1.4 The Synthesis of Calcitroic Acid

As these findings have shown, CTA is the most significant final metabolite of vitamin D.
When CTA was discovered by DeLuca in 1974, however, it was quickly characterized and then
mostly forgotten for forty years because it was
believed that no specific biological activity was
mediated by CTA. Recently, however, a study in
our lab unexpectedly found CTA to be active in
cells.4 For a VDR-mediated transcription assay,
our group found VDR target gene CYP24A1
upregulated in DU145 cells in the presence of

Figure 7: CYP24A1 gene regulation by VDR ligands (7.5 mM) in
DU145 cells after 18 hrs. Stars represent 0.001 P < (***)
compared to vehicle DMSO. Graph courtesy of Teske KA et al.4

CTA (Figure 7). The focus of this project has
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Scheme 2: Synthesis of CTA starting from a cholesterol analogue precursor

Scheme 3: Synthesis of CTA using a provitamin D precursor
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thus been to evaluate the biological activity of CTA in order to assess its function. Unfortunately,
CTA is not available commercially in the quantities required to study it fully, and is prohibitively
expensive even in small amounts (~$4000/mg).
The reason for the high price of CTA is that its isolation by both synthetic and enzymatic
methods have very low overall yields. The ﬁrst CTA synthesis was reported in 1981 (Scheme 2).91
The acetoxy derivative of Fernholz acid, which is commercially available from Steraloids, was
used as starting material and converted using an Arndt-Eistert reaction to the corresponding
higher carboxy homologue. Allylic bromination and subsequent elimination installed the diene,
which was converted in low yield under photochemical and thermal conditions to the methyl
ester of calcioic acid. 1α-hydroxylation was achieved by synthesizing a cyclovitamin D derivative
followed by allylic oxidation and cycloreversion with acetic acid. Hydrolysis gave CTA in an overall
yield of 0.09%. The optical rotation was not given, but the corresponding methyl ester coeluted
in HPLC with the derivatized material isolated from rat livers. Small improvements to this route
increased the overall yield to 0.28%.92
Two years later, a new route based on a previous synthesis of vitamin D analogs was
reported with an overall yield of 0.36% (Scheme 3).93 The synthesis started with 5,6dihydroergosterol, which was used to prepare the corresponding aldehyde. The carbon chain
elongation was carried out by a Wittig reaction followed by demethylation, oxidation, and
esteriﬁcation. A quinone-like structure was generated by oxidation, α-carbon bromination, and
elimination, which was subsequently isomerized and reduced to the allylic alcohol. The diene
and alcohol function were protected, followed by oxidation and subsequent deprotection. The
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retro Diels−Alder reaction recreated the diene, and conversion of the ester to the acid enabled a
selective reduction of the epoxide followed by esteriﬁcation. Finally, the seco-steroid scaﬀold

Scheme 5: Synthesis of CTA starting from a seco-steroid precursor

Scheme 4: Synthesis of CTA starting from vitamin D2 using a Ring A phosphine oxide synthon
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was produced by light and subsequent saponiﬁcation, generating CTA in 0.36% overall yield.
Importantly, the light-induced ring opening reaction reduced signiﬁcantly the overall yield of
both described methods.
During the 1980s and 1990s, many diﬀerent synthetic strategies were explored to
generate other vitamin D analogs, which led to the availability of many new synthons for their
synthesis.94 The carbon chain elongation using a seco-steroid as a starting material to produce
CTA was introduced in 1990 (Scheme 4).95 The starting material was a seleno acetal, which was
generated from the corresponding 1α-hydroxy vitamin D aldehyde derivative. Formylation gave a
lithio-demethylseleno derivative as a carbon homologue, which was protected as a hetero
Diels−Alder product with sulfur dioxide followed by radical deselenation induced by light. A retro
Diels−Alder reaction was achieved under mild conditions followed by oxidation and esteriﬁcation
to the corresponding ester. Photoisomerization installed the natural Z-conﬁguration of methyl
ester of the protected CTA, which was subsequently deprotected and hydrolyzed to give CTA.
The reactions described in Scheme 4 achieved high yields; however, the route has many steps if
the synthesis of the precursor would be included.
Very recently, a synthesis using commercially available chemicals was reported, that for
the ﬁrst time enabled the synthesis of gram quantities of CTA (Scheme 5).96 Originally developed
to generate 13C-labeled CTA for metabolic research, this synthesis used the Inhoﬀen Lythgoe
diol, which is both commercially available and readily synthesized from vitamin D2.97 This new
route was the foundation for our CTA production, which we modified in several ways to improve
reaction yields.
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1.5 Synthetic Strategy for Production of Calcitroic Acid

Synthesis of Inhoffen Lythgoe diol:98

OH
H

OH

H

HO

The Meyer synthesis used purchased Inhoffen Lythgoe diol.96 While we did initially
purchase some diol, we quickly decided that it would be less expensive to produce the diol using
ozonolysis from the much cheaper ergocalciferol (vitamin D2). We initially planned to use a
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reductive workup to isolate the aldehyde and convert it to the diol in a separate step. This
proved difficult because the aldehyde was difficult to purify and the yield was low. After we
learned from a collaborator that the reduction to the diol could be done in one-pot using sodium
borohydride, we changed our route to a one-pot two-step reaction to generate the Inhoffen
Lythgoe diol.
Even so, perfecting this reaction
was quite challenging. There were
multiple issues, starting with finding the
balance between enough MeOH to
support the ozonolysis process and
enough pyridine to dissolve
ergocalciferol. We were also unable to

Figure 8: Saturated with ozone, the MeOH/pyridine solution turns blue

get the reaction to reliably turn blue (saturate with O3) and needed to acquire a “fizzer” gas
dispersion fitting to bubble O3 through the solution with high surface area, allowing it to
saturate. Once those had been solved, there were additional issues realized as we attempted to
scale the reaction up; namely, we were unsuccessful scaling it up past the 3 g scale. A specific
round bottom flask (500mL, with a narrow outlet for used gas to escape) filled halfway was the
only way to get a balance between enough solvent in the proper proportions to dissolve 3 g of
vitamin D2, and having a large enough surface area-to-volume ratio to be able to keep the
solution at —78°C so the ozone could saturate the solution. Running the reaction for a full 7
hours at that temperature was generally the best way to ensure that all double bonds are
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oxidized. After allowing the reaction to warm up overnight, we added NaBH4 in tablet form one
at a time to limit the surface area and ensure that the solution did not overheat.
The workup remained a problematic issue for nearly the entire time that the diol was
being produced. After evaporation of the methanol, we were left with a large amount of
pyridine, which had been required to keep ergocalciferol in solution during the ozonolysis. We
were not able to evaporate pyridine or use azeotropic distillation to remove it from the product.
During the workup, the extracted DCM layer was washed multiple times with 1M HCl in an
attempt to protonate pyridine and dissolve it in the aqueous layer. This worked somewhat, but
still left plenty behind. Because pyridine and the diol were nearly overlapping via TLC plate, full
separation was never achieved via flash chromatography. We resorted to dealing with its
presence throughout the next step, until the tosylate protection rendered the product
sufficiently nonpolar to enable separation via flash chromatography.
However, on the final round of diol production, we used 10% CuSO4 for washing the
organic layer. This single wash removed all pyridine from the organic layer. As such, it is highly
recommended for eliminating pyridine in future syntheses.

28

Synthesis of O-silylated C,D-ring tosylate:

OH

OH

OTs

H

H
OTBS

The Meyer synthesis was followed for the
protection of the two alcohol functions
independently. The tosylate group on the primary
alcohol was carried out first, as it is the more
accessible alcohol. Thus, with one equivalent of
Ts-Cl, the primary alcohol will be selectively
Figure 9: Concentrated doubly-protected C,D-ring takes on a
slightly pink hue

protected in the presence of the secondary

alcohol. This reaction was reliable and gave the tosylated C,D-ring in high yield. The silyl ether
protecting group was added with a t-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf). This
protecting group is stable under weak acidic conditions, very stable under basic conditions and
readily removed in the presence of fluorine ions.
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Synthesis of O-silylated C,D-ring nitrile:

OTs

N
H
OTBS

H
OTBS

The Meyer synthesis’ carbon elongation
utilizes a classic route wherein the side chain’s
tosylate is a good leaving group for substitution
by potassium cyanide. In our lab, this reaction was
challenging and unreliable from the start. The
Meyer synthesis heated the reaction to 90°C, but
we found that this heat was sufficient to lose a
moderate portion of the product by loss of the
silyl protecting group (20-60%), even if closely
monitored and quenched as soon as the starting
material was gone. Even reactions with minimal
degradation faced a more severe problem: loss of
product during workup. Initially, the reaction was

Figure 10: Nitrile reaction turns red as we attempt to get
salts into solution. When sonicated/heated, sometimes it
turned green when everything was in solution

carried out in DMSO—a necessary concession when dealing with organic compounds that need
to react with inorganic salts (NaOH and KCN). For the workup, the reaction was dissolved in 1050x the volume of water and extracted with ethyl acetate, but it still resulted in a large amount
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of DMSO in the organic layer. Excessive washing of the organic layer with water until the DMSO
disappeared resulted in unacceptably low yields. This was observed across the many different
workup procedures we tried, which included: extraction with many solvents, especially ones
known not to dissolve DMSO very well; using an excessive amount of water to dilute DMSO;
using a recursive extract/wash system with a series of separatory funnels to get progressively
less DMSO and more organic product; using DMF instead of DMSO (similar problems) and using
ACN instead of DMSO (no conversion).
Unable to produce good results, we changed the method. ACN on its own was unable to
solubilize the salts enough for the reaction to proceed at any temperature. However, a polar but
volatile solvent would change the difficulty of this reaction workup entirely, so we tried another
method: crown ethers. It is well-known that 18-crown-6 readily solubilizes K+ ions. While
potassium wasn’t the ion of interest for purposes of substitution, the strong affinity of 18-crown6 for K+ causes the “naked ion” effect for CN—, wherein it becomes an even better nucleophile in
the absence of its balancing cation. This altered reaction was highly successful when run at 75°C,
with no trouble during the workup and an improved yield around 93%.
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Synthesis of O-silylated C,D-ring aldehyde:

H
N
H
OTBS

O
H
OTBS

The side-chain modification continues, converting the nitrile in three steps to the
aldehyde, to the acid, and then to the ester. The reduction of the
nitrile to the aldehyde was carried out with DIBAL in dry DCM at 0°C.
During the quench it should be noted that the reaction needs to be
kept at 0°C throughout. The addition of aqueous NH4Cl to quench the
DIBAL is extremely exothermic and prone to bubbling over, especially
during the first few drops. We found that the quenched reaction does
need to stir for at least a half hour before breaking up the viscous

Figure 11: Fluffy quenched DIBAL
following aq. NH4Cl addition and
TBME dilution is ready for drying

solution with t-butyl methyl ether (TBME). Once TBME was added, the reaction needed to stir at
0°C for as long as necessary until the aqueous layer separated more thoroughly, forming a white
fluffy gelatin that typically balled up and adhered to the flask somewhere (Figure 11). Rushing
these steps results in loss of product, possibly because intermediate imines are not fully
hydrolyzed to the aldehyde. Only then is it appropriate to begin drying off the aqueous layer,
which is done simply by adding a large amount of MgSO4 until a dry solution is achieved.
Breaking up the solidified MgSO4 as best as possible is advised in order to allow any product
trapped within the gelatin to dissolve into the organic layer. Because the nitrile and aldehyde are
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almost overlapping via TLC, it is important that this reaction run to completion before it is
quenched; otherwise separation between the two is impossible by chromatography.
In the case that the 13C labeling will not lead to a compound distinguishable by MS from
non-labeled CTA, a secondary plan to label the compound with an 18O during this step is
proposed. In this reaction, DIBAL reacts with the nitrile to form an intermediate imine. The
intermediate imine is hydrolyzed by water to form an aldehyde, acquiring the oxygen molecule
from the water. As such, quenching the reaction using 18O heavy water would add another label
to the final product.

Synthesis of O-silylated C,D-ring acid:

H

OH

O

O

H
OTBS

H
OTBS

The conversion of the aldehyde to the acid is a
Pinnick oxidation. In this reaction, chlorous acid is
formed from chlorite under acidic conditions as the
oxidant. Chlorous acid adds to the aldehyde and then
undergoes pericyclic fragmentation to produce the acid
function and hypochlorous acid (HOCl). The presence of
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Figure 12: Faintly seen aqueous and organic layers
as reaction turns yellow in Pinnick oxidation

the HOCl scavenger 2-methyl-2-butene then ensures that the species will not go on to destroy
other NaClO2 ions (which would prevent them from completing the oxidation) or produce other
unwanted byproducts.99 This reaction is a little unusual in that it uses mixed aqueous and organic
phases. The starting material is dissolved in t-butanol, with the 2-methyl-2-butene hypochlorous
acid byproduct scavenger added. The NaClO2 is then dissolved separately in water containing the
stabilizer/buffer NaH2PO4. The water layer is then added to the organic, and a yellow-green
solution is immediately observed. The color fades as the reaction proceeds. While this reaction
can be separated via chromatography, we found that all byproducts were easily removed during
the workup: upon extraction, NaH2PO4, NaClO2, HOCl and its scavenger byproduct went into the
aqueous layer while t-butanol and 2-methyl-2-butene were removed through concentration.
Thus, by proceeding directly to the next reaction, we returned higher yields.

Synthesis of O-silylated C,D-ring ester:

O

OH

O

O
H
OTBS

H
OTBS

For the esterification, the methylating agent
trimethylsilyldiazomethane was used, which was added dropwise through
a septum into the dry toluene/MeOH reaction mixture. The mixture turns
34

Figure 13: Trimethylsilyldiazomethane turns the methylating
reaction yellow

yellow to indicate the presence of the diazo compound, and when complete it can be quenched
with acetic acid, turning the solution clear again. The solution is then concentrated and purified
directly via column (quantitative yield).

Synthesis of C,D-ring alcohol:

O

O

O

O
H
OTBS

OH

H

The reaction to deprotect the silyl group to an alcohol group using TFA worked fine
during the first rounds of synthesis. However, when we were reacting more material, a
previously trace byproduct spot took over about half of the reaction yield. While we were unable
to identify this byproduct, we inadvertently discovered how to convert it to the desired C,Dalcohol product. We separated the desired deprotected alcohol product from the rest of the
crude (which contained both unreacted silyl-protected C,D-ring alcohol and the unknown
byproduct). The crude was then re-reacted with TBAF, anticipating that what remained
unreacted would instead form product, and the byproduct would just be a loss. Instead, we saw
the byproduct spot disappear to form the desired C,D-ring alcohol product, while the unreacted
starting material remained untouched. Continued reactions made clear that this was the best
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way to manage the large amount of byproduct that formed: first, the reaction was run with TFA
to form both anticipated product and byproduct, and then a second reaction was run to convert
the byproduct to the anticipated product. Eventually, all the silyl-protected substrate was
converted to the alcohol in an overall improved yield across the two reactions (89%).

Synthesis of C,D-ring ketone:

O

O
O

O

OH

H

O

H

Following the Meyer synthesis again, we then
oxidized the alcohol to the ketone. The reaction is best run
under nitrogen at room temperature and proceeds fairly
well as long as the DCM is dry. It is important for the PDC to
be very freshly ground prior to the reaction to expose the
unoxidized surface, which is orange instead of brown or
black. As PDC does not dissolve in DCM, a suspension will

Figure 14: Finely ground, oxidized PDC
turning black during the reaction

form that turns black as the reaction proceeds. The reaction
appears to be complete within 3 hours, but it is best to run overnight to ensure complete
conversion, as both starting material and product have the same Rf and thus cannot be
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separated by chromatography. Completion can be confirmed by NMR. It is important to remove
all product off the solid PDC. Filtering over celite, then re-suspending the solids in fresh DCM
with vigorous stirring at least three more times led to improved yields (up to 20% improvement).

Synthesis of O-Bis-silylated calcitroic acid methyl ester:

The Wittig-Horner ligation was the most challenging reaction in the synthesis of CTA, and
prone to failure and low yields. Successful, moderate-yield reactions required extensive planning,
careful controlled execution, and extremely dry conditions. To begin with, solid ketone and solid
commercially-acquired organophosphine oxide (ring A synthon) ligand were never dry enough to
use because transferring them brings them in contact with air, and the solid can trap water.
Instead, they needed to be dissolved in THF and dried overnight in small, oven-dried flasks with
molecular sieves. The glassware setup needed to be oven dried overnight and assembled in its
entirety while hot (including dropping funnel, molecular sieves in both RBF and funnel, and stir
bar), then vacuum and nitrogen purged multiple times as it cooled. Once set, it must remain
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under nitrogen and cannot be opened to air; instead, a dropping funnel and syringes were used
to transfer/add the reagents.

Figure 15: Wittig-Horner reaction at different stages. From left to right: the deprotonation of organophosphine oxide
by n-BuLi; reaction color darkened upon brief removal from dry ice bath to ensure full consumption of n-BuLi; an
unsuccessful reaction turned peach color when quenched by water.

During the first stage, the phosphine oxide solution was added to the 3-neck RBF from
the side neck and the solution was cooled to —78°C. N-butyl lithium was added via syringe
through the side neck, and a brilliant red color resulted. This color is the main indication of
success in the reaction, as its loss indicates that the reaction is exposed to water or that
unreacted n-BuLi attacked the ketone (1,2 addition) instead of deprotonating the phosphine
oxide. While the molar ratio of the n-BuLi must be higher than that of the ketone being added, it
must be lower than that of the phosphine oxide it is deprotonating (recommended 1:1.5 or
greater). After an hour of stirring, the reaction was briefly suspended above the dry ice bath,
allowing it to reach a higher temperature and ensure full consumption of the n-BuLi. The color
darkened to deep blood red (see Figure 15). The reaction was then cooled again to —78°C. In
the second phase, the ketone was added from the dropping funnel. This needed to be done very
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slowly to ensure that the reaction does not warm up significantly. Also, careful monitoring of the
color of the solution was necessary. If the reaction started to lose its color, and especially if a
quick conversion to yellow was seen, the reaction was aborted immediately and no more ketone
was added. Any ketone that had already been added could not be recovered due to 1,2-addition
by the n-BuLi, so watching this step carefully was imperative. The reaction could then be
monitored by TLC, but samples could only be extracted via syringe, as opening the reaction
results in noteworthy product loss. The reaction ran for up to 5 hours, then was quenched with
water and warmed to room temperature for work-up. The quenched reaction was extracted
with TBME, the extract washed with brine, concentrated and purified by column
chromatography (78% yield).

Synthesis of calcitroic acid methyl ester:

O

O

O

O

H

TBSO

H

OTBS

HO
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OH

The subsequent TBAF deprotection of the A-ring synthon’s silyl ethers needs to be kept
very dry and uses ten equivalents of TBAF in order to get excellent yields. This reaction was the
highest-yielding option for small reactions. However, for large reactions TBA was difficult to
separate from the product. Generally speaking, formation of the TBA-Cl salt using NH4Cl washes
dissolves TBA in the water layer. In practice, even an excessive number of washes does not fully
remove TBA from the organic layer. This was okay for small reactions, where the TBA would then
be separated via column chromatography, but in larger batches there was far too much leftover
TBA even after extraction, and it co-eluted with the product. This problem is bypassed by instead
using camphorsulfonic acid (CSA) as a convenient, speedy alternative, requiring only about 15
minutes of reaction and yielding a very clean product after workup. Because of this, the CSA
product could be used in the next step without purification, but the yield across the two
reactions when we used CSA was never as high as the yield when we used TBAF.
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Synthesis of calcitroic acid:

O

OH

O

O

H

HO

H

OH

HO

OH

The final reaction of the CTA synthesis is the hydrolysis from the methyl ester to the acid.
This synthesis had been previously reported using KOH at 60°C for 1.5 hours. When we struggled
to carry out this reaction, we tried several alternate hydrolysis options. We discovered that using
room temperature and NaOH resulted in better yields (84% compared to 74%) and avoided the
compound degradation that we had been seeing at elevated temperatures.

Discussion

Overall, the Meyer group reported a yield of 12.8% for CTA. This is an impressive
improvement over the 0.36% reported earlier. Our improved synthesis starting from the
Inhoffen Lythgoe diol had an overall 29% yield. While it was more cost-effective in our lab to
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start from ergocalciferol rather than purchasing the diol, the low yield (57%) of the initial
ozonolysis and reduction steps decreased the yield for all 13 steps to 16%. Using K13CN to
substitute a labeled carbon as outlined by Meyer also afforded the 13C-labeled CTA in the same
yield. As an alternate product, the same method was utilized to generate the vitamin D
metabolic product calcioic acid: the corresponding A-ring synthon is commercially available and
afforded the corresponding O-silylated calcioic acid methyl ester in comparable yields. Using our
variation of the Meyer synthetic method, a total of 3.2g of CTA was able to be generated. This
material was used to both characterize CTA, provide the substance to various collaborators, and
as a scaffold from which to synthesize a variety of secondary metabolic products for CTA.
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1.6 Characterization of Calcitroic Acid Synthesis Compounds

Ergocalciferol was purchased from variable commercial sources (Alfa Aesar J62163,
AstaTech 44109, Research Products International C20300, Sigma-Aldrich 95220, VWR 101172472). Both of the phosphine oxides were purchased from ChemScene (CS-M1835, CS-M0003). All
moisture or oxygen-sensitive reactions were carried out under a dry nitrogen atmosphere.
Reaction temperatures refer to the containing bath temperatures. Reactions were monitored by
thin-layer chromatography (TLC) using Merck 60 UV254 silica gel plates (Sigma-Aldrich).
Visualization was performed with UV light, cerium molybdate general stain followed by heating,
and other methods as noted. Synthesized compounds were purified by normal phase flash
chromatography (SPI Biotage, silica gel 230-400 mesh) except where noted. Compound
characterization was performed via Shimadzu 2020 LC-MS (single quadrupole) instrument. NMR
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spectra were recorded on a Bruker Avance 500MHz instrument with compounds dissolved in the
specified deuterated solvent. Optical rotations were recorded using Jasco DIP-370 Digital
Polarimeter instrument in LCMS grade chloroform or methanol.

Inhoffen-Lythgoe diol: Ergocalciferol (3g, 7.5mmol) was dissolved first in
OH

OH

H

dry pyridine (7mL), and then that mixture was diluted in dry methanol
(250mL). The 500mL RBF used was single-necked with a diffuse bubbler as
the inlet for ozone and a slim outlet for the dissipating gas. The reaction

mixture was cooled to -78°C and ozone was bubbled through it for 4-6 hours using an A2Z Ozone
A2ZZ-5G 110 V with 38g/m3 O3 output. The reaction was monitored by TLC (UV and cerium
molybdate). Many spots occur initially, which reduce to three main spots after several hours.
One of the two lower spots, partially overlapping with the pyridine spot (Rf 0.10 EtOAc:Hex 1:3)
is the product. When no more change was apparent after an additional hour of ozonolysis, the
reaction mixture was then brought to 0°C and stirred vigorously. Sodium borohydride (2g,
53mmol) was added carefully. Once fully dissolved, the reaction was quenched with 70mL of
water and stirred for 5 minutes before concentrating. The crude reaction mixture was diluted
with 100mL of water and extracted with DCM (3x100mL). The organic layers were washed with
5% CuSO4 solution (100mL), 1M HCl (2x100mL) and saturated NaHCO3 (100mL), dried over
MgSO4, concentrated, and purified by column chromatography (EtOAc:Hex 1:3) to yield the
Inhoffen Lythgoe diol as a white solid (450mg, 57%). Note that this reaction could not be scaled
up, as larger percentages of pyridine were not tolerated and larger reaction vessels could not be
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adequately cooled in order to allow ozone saturation. Rf 0.09 (EtOAc: Hex 1:3); 1H-NMR
(500MHz, CDCl3) δ 0.97 (s, 3H), 1.04 (d, J = 5.0, 3H), 1.14-1.23 (m, 2H), 1.31-1.40 (m, 2H), 1.411.53 (m, 5H), 1.54-1.62 (m, 2H), 1.78-1.91 (m, 3H), 1.98-2.04 (m, 1H), 3.38 (dd, J = 5.0, 3.5 Hz,
1H), 3.65 (dd, J = 10, 3.0 Hz, 1H), 4.10 (d, J = 2.0, 1H); 13C-NMR: (125MHz, CDCl3) δ 13.6, 16.6,
17.4, 22.6, 26.7, 33.5, 38.2, 40.2, 41.8, 52.4, 53.0, 67.6, 69.2; m/z calculated for C13H24O2 211 [M
— H],— found 211; [𝛼]25
𝐷 = + 24.0 (c 1.0, CHCl3)

C,D-ring tosylate: To a stirred solution of Inhoffen-Lythgoe diol (0.38g,
OTs

1.78mmol) in dry DCM (20mL) was added 4-dimethylaminopyridine
OH

H

(DMAP; 0.44g, 3.58mmol) and p-toluenesulfonyl chloride (0.36g,

1.88mmol). The reaction was stirred overnight at room temperature, then quenched with 1 M
HCl (20mL). The reaction mixture was extracted with DCM (3x50mL) and combined organic
layers were washed with water (50mL), dried over MgSO4, and purified by column
chromatography (EtOAc:Hex 3:7) to yield C,D-ring tosylate as a white crystalline solid (410mg,
84%); Rf 0.23 (EtOAc: Hex 1:3); 1H-NMR (500MHz, CDCl3) δ 0.92 (s, 3H), 1.00 (d, J = 5.0 Hz, 3H),
1.13-1.26 (m, 4H), 1.31-1.38 (m, 1H), 1.42-1.51 (m, 3H), 1.52-1.62 (m, 1H), 1.66-1.75 (m, 2H),
1.77-1.88 (m, 2H), 1.92-1.98 (m, 1H), 2.48 (s, 3H), 3.84 (dd, J = 6.5, 3.0 Hz, 1H), 3.98 (dd, J = 6.2,
3.0 Hz, 1H), 4.10 (s, 1H), 7.38 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.5 Hz, 2H); 13C-NMR: (125MHz,
CDCl3) δ 13.49, 16.75, 17.35, 21.65, 22.46, 26.42, 33.56, 40.06, 41.88, 52.25, 52.26, 69.06, 75.61,
127.92 (2C), 129.79 (2C), 133.10, 144.64; m/z calculated for C20H30O4S 430 [M + Na + ACN],+
found 430; [𝛼]25
𝐷 = + 19.0 (c 1.0, CHCl3)
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O-silylated C,D-ring tosylate: To a solution of C,D-ring tosylate (0.40g,
OTs

1.09mmol) in dry DCM (2mL) at 0°C was added 2,6-lutidine (0.15mL,
1.31mmol) and tert-butyl dimethylsilyl trifluoromethanesulfonate

H
OTBS

(0.35mL, 1.53mmol). The reaction was monitored by TLC until completion
(2 hours) and quenched with water (2mL). The crude mixture was extracted with DCM (3x15mL),
washed with water (15mL), dried over MgSO4, concentrated, and purified by column
chromatography (EtOAc : Hex 1:19) to yield O-silylated C,D-ring tosylate as a clear or slightly pink
oil, which solidified during storage (0.32g, 62%); Rf 0.43 (EtOAc: Hex 1:19); 1H-NMR (500MHz,
CDCl3) δ 0.00 (s, 3H), 0.02 (s, 3H), 0.88 (s, 3H), 0.89 (s, 9H), 0.97 (d, J = 6.5, 3H), 1.08-1.19 (m,
3H), 1.19-1.26 (m, 1H), 1.26-1.42 (m, 3H), 1.49-1.57 (m, 1H), 1.58-1.71 (m, 3H), 1.73-1.84 (m,
1H), 1.86-1.92 (m, 1H), 2.47 (s, 3H), 3.82 (dd, J = 6.5, 2.8 Hz, 1H), 3.95-4.02 (m, 2H), 7.36 (d, J =
8.0 Hz, 2H), 7.80 (d, J = 10.2 Hz, 2H); 13C-NMR: (125MHz, CDCl3) δ –5.2, –4.8, 13.7, 16.8, 17.6,
18.0, 21.6, 23.0, 25.8 (4C), 26.5, 34.3, 35.8, 40.4, 42.2, 52.4, 52.7, 69.2, 75.8, 127.9 (2C), 129.8
(2C), 133.2, 144.6; m/z calculated for C26H48O4NSSi 499 [M + NH4],+ found 499; m/z calculated for
C28H47O4NSSiNa 544 [M + Na + ACN],+ found 544; [𝛼]25
𝐷 = + 34.0 (c 1.0, CHCl3)

O-silylated C,D-ring nitrile: To a solution of O-silylated C,D-ring tosylate
N
H
OTBS

(2.74 g, 5.70 mmol) in dry acetonitrile (75mL) was added NaOH (0.46 g,
11.40mmol), potassium cyanide (0.74g, 11.40mmol), and 18-crown-6
(3.77g, 14.25mmol). The solution was stirred at 75°C for 2.5 hours or until
46

the starting material disappeared by TLC. Acetonitrile was removed under reduced pressure and
the residue was dissolved in water (20mL) and extracted with EtOAc (3 x 20mL). The combined
organic layers were washed with brine, dried over MgSO4, concentrated, and purified by column
chromatography (EtOAc : Hex 3 : 97) to yield the O-silylated C,D-ring nitrile (1.80g, 94%) as a
clear oil; Rf 0.20 (EtOAc: Hex 3:97); 1H-NMR (500MHz, CDCl3) δ 0.02 (s, 3H), 0.04 (s, 3H), 0.91 (s,
9H), 0.95 (s, 3H), 1.16 (d, J = 6.6Hz, 3H), 1.18-1.29 (m, 3H), 1.30-1.36 (m, 1H), 1.37-1.46 (m, 3H),
1.56-1.66 (m, 1H), 1.67-1.73 (m, 1H), 1.75-1.88 (m, 3H), 1.92-1.97 (m, 1H), 2.25 (dd, J = 16.6, 7.0
Hz, 1H), 2.36 (dd, J = 16.6, 3.8 Hz, 1H), 4.01-4.04 (m, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.2, –4.8,
13.9, 17.5, 18.0, 19.3, 22.9, 24.7, 25.8 (3C), 27.2, 33.1, 34.2, 40.3, 42.2, 52.9, 55.4, 69.2, 119.1;
m/z calculated for C20H41N2OSi 354 [M + NH4],+ found 354; [𝛼]25
𝐷 = + 48.0 (c 1.0, CHCl3)

O-silylated C,D-ring aldehyde: To a stirred solution of O-silylated C,D-ring
H
O
H
OTBS

nitrile (0.69g, 2.06mmol) in 20mL dry DCM at 0°C was added a solution of
DIBAL (1.5 M in toluene, 4.80mL, 7.19mmol) dropwise. The reaction was
monitored at 0°C for 45 minutes until complete by TLC. The reaction was

then carefully quenched with 10mL of a saturated solution of NH4Cl (aq) and stirred for an hour
at 0°C. The viscous solution was then broken up by stirring in TBME (60mL), which was kept at
0°C for another two hours and then allowed to warm up overnight. The aqueous layer formed a
fluffy white ball, which was dried off directly with MgSO4 and filtered. The organic filtrate was
concentrated under reduced pressure and purified via column chromatography (EtOAc : hexanes
5 : 95) to yield the O-silylated C,D-ring aldehyde (0.66g, 94%) as a clear oil: (Rf 0.41 (EtOAc: Hex
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7:93); 1H-NMR (500MHz, CDCl3) δ 0.02 (s, 3H), 0.04 (s, 3H), 0.91 (s, 9H), 0.98 (s, 3H), 1.02 (d, J =
6.5 Hz, 3H), 1.12-1.19 (m, 2H), 1.23-1.30 (m, 2H), 1.36-1.43 (m, 3H), 1.56-1.65 (m, 1H), 1.67-1.73
(m, 1H), 1.76-1.86 (m, 2H), 1.94-2.00 (m, 1H), 2.02-2.09 (m, 1H), 2.13-2.19 (m, 1H), 2.47 (dd, J =
15.7, 2.5 Hz, 1H), 4.01-4.04 (m, 1H), 9.70 (dd, J = 3.6, 1.4 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ –
5.2, –4.8, 13.7, 17.6, 18.0, 20.0, 23.0, 25.8 (3C), 27.6, 31.3, 34.3, 40.6, 42.3, 50.8, 53.0, 56.6,
69.3, 203.7; m/z calculated for C20H41N2OSi 354 [M + NH4],+ found 354; [𝛼]25
𝐷 = + 27.0 (c 1.0,
CHCl3)

O-silylated C,D-ring acid: Sodium phosphate monobasic monohydride
OH
O
H
OTBS

(3.39g, 24.55mmol) was dissolved in 32mL of H2O. To this was added
sodium chlorite (3.41g, 37.65mmol). The aqueous solution was then
added to a stirred solution of O-silylated C,D-ring aldehyde (1.39g,

4.09mmol) in tert-butanol (77mL) and 2-methyl-2-butene (19mL). The reaction was monitored
for 1 hour until completion and then concentrated under reduced pressure. The residue was
dissolved in H2O and extracted with DCM (3x50mL). The organic layers were washed with water
(20mL), dried over MgSO4 and concentrated to the O-silylated C,D-ring acid (3.2g, 99%) as a
white powder: Rf 0.19 (EtOAc: Hex 1:4); 1H-NMR (500MHz, CDCl3) δ 0.02 (s, 3H), 0.03 (s, 3H),
0.91 (s, 9H), 0.97 (s, 3H), 1.03 (d, J = 6.4 Hz, 3H), 1.08-1.19 (m, 2H), 1.25-1.31 (m, 2H), 1.33-1.42
(m, 3H), 1.55-1.65 (m, 1H), 1.66-1.72 (m, 1H), 1.77-1.88 (m, 2H), 1.91-2.08 (m, 3H), 2.49 (d, J =
14.8, 3.2 Hz, 1H), 4.01-4.04 (m, 1H), 11.05 (bs, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.2, –4.8, 13.7,
17.6, 18.0, 19.5, 23.0, 25.8 (3C), 27.3, 33.2, 34.4, 40.6, 41.2, 42.3, 53.0, 56.5, 69.4, 179.7; m/z
48

calculated for C20H38O3Si 356 [M + H]+ , found 356; m/z calculated for C20H38O3Si 353 [M — H],—
found 353; [𝛼]25
𝐷 = + 41.0 (c 1.0, CHCl3)

O-silylated C,D-ring methyl ester: To a stirred solution of O-silylated C,DO

ring acid (1.01g, 2.86mmol) in 16.5mL toluene and 11mL MeOH was

O

added trimethylsilyl diazomethane (2.12mL, 2M in diethyl ether,

H
OTBS

4.23mmol). The reaction was stirred for 1.5 hours at room temperature
and then quenched with acetic acid. The mixture was concentrated under reduced pressure and
purified by column chromatography (EtOAc : hexanes 3 : 97) to yield the O-silylated C,D-ring
ester (1.05g, quantitative) as a clear oil: Rf 0.28 (EtOAc: Hex 3:97); 1H-NMR (500MHz, CDCl3) δ
0.01 (s, 3H), 0.02 (s, 3H), 0.90 (s, 9H), 0.95-0.98 (m, 6H), 1.06-1.17 (m, 2H), 1.24-1.30 (m, 2H),
1.33-1.49 (m, 3H), 1.54-1.64 (m, 1H), 1.65-1.71 (m, 1H), 1.74-1.87 (m, 2H), 1.89-2.03 (m, 3H),
2.43 (dd, J = 14.2, 3.1 Hz, 1H), 3.67 (s, 3H), 3.99-4.03 (m, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.2,
–4.8, 13.8, 17.6, 18.0, 19.5, 23.0, 25.8 (3C), 27.3, 33.4, 34.4, 40.6, 41.3, 42.2, 51.3, 53.0, 56.6,
69.4, 174.0; m/z calculated for C21H39O3Si 367 [M — H],— found 367; [𝛼]25
𝐷 = + 41.0 (c 1.0, CHCl3)

Methyl esterified C,D-ring alcohol: To a stirred solution of O-silylated
O
O

OH

H

C,D-ring ester (1.48g, 4.01mmol) in dry DCM (45mL) at 0°C was added
trifluoroacetic acid (4.5mL, 58.4mmol). The reaction was stirred at 0°C for
1.5 hours until it was complete by TLC. The reaction mixture was

concentrated under reduced pressure and purified by column chromatography (EtOAc : hexanes
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1 : 4) to yield the esterified C,D-ring alcohol (0.93g, 91%) as a clear oil: Rf 0.32 (EtOAc: hexanes
1:4); 1H-NMR (500MHz, CDCl3) δ 0.96-1.00 (m, 6H), 1.09-1.21 (m, 2H), 1.29-1.40 (m, 3H), 1.401.53 (m, 3H), 1.55-1.65 (m, 1H), 1.78-1.89 (m, 3H), 1.89-1.97 (m, 1H), 1.97-2.05 (m, 2H), 2.44
(dd, J = 14.2, 3.2 Hz, 1H), 3.68 (s, 3H), 4.08-4.11 (m, 1H); 13C-NMR: (125MHz, CDCl3) δ 13.6, 17.4,
19.4, 22.5, 27.2, 33.4, 33.6, 40.3, 41.3, 42.0, 51.4, 52.6, 56.4, 69.2, 174.0; m/z calculated for
C16H27O5 299 [M + FA — H],— found 299; C17H26O5F3 367 [M + TFA — H],— found 367; [𝛼]25
𝐷 =+
30.0 (c 1.0, CHCl3)

Methyl esterified C,D-ring ketone: To a stirred solution of C,D-ring alcohol
O
O

O

H

(0.653g, 2.57mmol) in dry DCM (50mL) was added freshly ground PDC
(1.93g, 5.13mmol). The reaction was monitored for two hours at room
temperature, then diluted with TBME (50mL) and filtered over celite. The

filtered solid was resuspended twice more in fresh DCM (2x25mL) and stirred vigorously for a
half hour each before being filtered again. The combined filtrates were concentrated under
reduced pressure and purified via column chromatography (EtOAc : hexanes 1 : 4) to yield the
C,D-ring ketone (0.565g, 87%) as a white solid: Rf 0.35 (EtOAc: Hex 1:4); 1H-NMR (500MHz,
CDCl3) δ 0.63 (s, 3H), 0.98 (d, J = 6.5, 3H), 1.26-1.36 (m, 1H), 1.42-1.60 (m, 3H), 1.66-1.76 (m,
1H), 1.78-1.93 (m, 3H), 1.94-2.04 (m, 2H), 2.04-2.09 (m, 1H), 2.14-2.27 (m, 2H), 2.36-2.46 (m,
2H), 3.62 (s, 3H); 13C-NMR: (125MHz, CDCl3) δ 12.5, 19.0, 19.5, 23.9, 27.4, 33.3, 38.8, 40.8, 41.0,
49.8, 51.4, 56.2, 61.8, 173.5, 211.5; m/z calculated for C15H24O3 253.1798 [M + H]+, found
253.1766; [𝛼]25
𝐷 = — 5.0 (c 1.0, CHCl3)
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O-Bis-silylated calcitroic acid methyl ester: A solution of nO
O
H

butyllithium (1.6 M in hexanes, 1.56mL, 2.50mmol) was added
dropwise to a solution of the CTA A-ring phosphine oxide
(1.84g, 3.16mmol, dried over 3Å molecular sieves in 5 ml THF

TBSO

OTBS

overnight) at —78°C in the presence of freshly dried 3Å

molecular sieves. The solution turned deep red and was stirred for an hour at —78°C. Raising the
solution out of the bath briefly deepened the red color and ensured that the deprotonation was
complete. The solution was returned to the bath and C,D-ring ketone (0.42g, 1.66mmol, dried
over 3Å molecular sieves in 5 ml THF overnight) was added dropwise. The solution was stirred
for 5 hours at -78°C and then allowed to come to room temperature. The reaction mixture was
then quenched with 10mL water, diluted with TBME, and extracted (TBME, 2x50mL). Combined
organic layers were washed with brine, dried over MgSO4, and concentrated. The crude product
was purified by column chromatography (EtoAc: Hex 5:95) to yield O-Bis-silylated CTA methyl
ester (0.66g, 65%) as a viscous white oil; Rf 0.22 (EtOAc:Hex 3:97); 1H-NMR (500MHz, CDCl3) δ
0.04-0.10 (m, 12H), 0.58 (s, 3H), 0.89 (s, 18H), 1.00 (d, J = 6.3 Hz, 3H), 1.26-1.36 (m, 3H), 1.461.61 (m, 3H), 1.61-1.73 (m, 2H), 1.73-1.81 (m, 1H), 1.81-1.96 (m, 3H), 1.96-2.05 (m, 3H), 2.22
(dd, J = 12.6, 7.6 Hz, 1H), 2.40-2.48 (m, 2H), 2.80-2.86 (m, 1H), 3.66 (s, 3H), 4.17-4.23 (m, 1H),
4.35-4.40 (m, 1H), 4.84-4.89 (m, 1H), 5.16-5.20 (m, 1H), 6.03 (d, J = 11.2 Hz, 1H), 6.24 (d, J = 11.2
Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.1, –4.8, –4.68, –4.67, 12.0, 18.1, 18.2, 19.7, 22.1, 23.4,
25.8, 25.9, 27.7, 28.8, 34.1, 40.5, 41.3, 44.8, 45.8, 46.1, 51.3, 56.3 (2C), 67.5, 72.1, 111.3, 118.1,
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123.1, 135.2, 140.5, 148.3, 173.84; m/z calculated for C38H67NO4Si2Na 681 [M + ACN + H],+ found
681; [𝛼]25
𝐷 = + 21.0 (c 1.0, CHCl3)

O-bis-silylated calcitroic acid: To a stirred solution of O-BisOH
O
H

silylated CTA methyl ester (101.0mg, 0.16mmol) in minimal
MeOH (5mL) was added a solution of 10% NaOH (%w/v) in
MeOH:H2O 9:1. The reaction stirred overnight at room

TBSO

OTBS

temperature, then was neutralized with concentrated HCl to

~pH 6. The neutralized reaction mixture was concentrated under reduced pressure to remove
MeOH, then diluted with H2O (20mL). The mixture was extracted once with DCM, then acidified
to pH 1 with concentrated HCl, and extracted with DCM again (3x20mL). Combined organic
layers were dried over MgSO4 and concentrated to the O-bis-silylated CTA (70.5mg, 71%) as a
white powder. No attempts were made to purify the product further; Rf 0.18 (EtOAc: Hex 1:7);
1H-NMR

(500MHz, CDCl3) δ 0.07-0.10 (m, 12H), 0.60 (s, 3H), 0.90 (s, 18H), 1.07 (d, J = 6.4 Hz, 3H),

1.29-1.39 (m, 3H), 1.49-1.60 (m, 3H), 1.64-1.74 (m, 2H), 1.76-1.82 (m, 1H), 1.86-2.10 (m, 7H),
2.24 (dd, J = 13.2, 7.5 Hz, 1H), 2.45-2.54 (m, 2H), 2.82-2.88 (m, 1H), 4.19-4.24 (m, 1H), 4.39 (dd, J
= 6.6, 3.4 Hz, 1H), 4.89 (d, J = 2.5 Hz, 1H), 5.20 (d, J = 1.75 Hz, 1H), 6.04 (d, J = 11.2 Hz, 1H), 6.26
(d, J = 11.2, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.1, –4.8, –4.68, –4.67, 12.0, 18.15, 18.23, 19.7,
22.1, 23.4, 25.8 (3C), 25.9 (3C), 27.7, 28.8, 34.0, 40.5, 41.1, 44.8, 45.8, 46.1, 56.2, 56.3, 67.5,
72.1, 111.3, 118.1, 123.1, 135.3, 140.6, 148.3, 178.9; m/z calculated for C35H62O4Si2 603.4259 [M
+ H]+, found 603.4147; [𝛼]25
𝐷 = + 26.0 (c 1.0, CHCl3)
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Calcitroic acid methyl ester: Tetrabutylammonium fluoride (1M in
O
O
H

THF, 23mL, 23.3mmol) was added to a stirred solution of O-bissilylated CTA methyl ester (0.96g, 1.55mmol) in dry THF (20mL)
at room temperature. The solution was stirred overnight,

HO

OH

quenched with saturated NH4Cl solution (20mL) and extracted

with EtOAc (3x50mL). The combined organic layers were washed with brine (50mL), dried over
MgSO4, concentrated, and separated by column chromatography (EtOAc : Hex 7 : 3) to yield CTA
methyl ester as a slightly yellow oil (0.53g, 88%); Rf 0.26 (EtOAc: Hex 7:3); 1H-NMR (500MHz,
CDCl3) δ 0.57 (s, 3H), 0.98 (d, J = 6.4 Hz, 3H), 1.27-1.34 (m, 3H), 1.45-1.59 (m, 4H), 1.63-1.72 (m,
2H), 1.81-1.95 (m, 4H), 1.96-2.03 (m, 4H), 2.30 (dd, J = 14.0, 8.0 Hz, 1H), 2.43 (dd, J = 14.5, 3.5
Hz, 1H), 2.57 (dd, J = 13.7, 3.1 Hz, 1H), 2.82 (dd, J = 12.6, 4.3 Hz, 1H), 3.66 (s, 3H), 4.21 (m, 1H),
4.42 (dd, J = 7.6, 4.5 Hz, 1H), 4.98 (s, 1H), 5.32 (s, 1H), 6.02 (d, J = 11.0 Hz, 1H), 6.35 (d, J = 11.0
Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ 12.0, 19.6, 22.2, 23.5, 27.6, 29.0, 34.1, 40.3, 41.3, 42.8,
45.2, 45.9, 51.4, 56.3 (2C), 66.7, 70.6, 111.8, 117.3, 124.6, 133.4, 142.5, 147.7, 174.0; m/z
calculated for C24H36O4 389.2686 [M + H]+, found 389.2618; [𝛼]25
𝐷 = —7.0 (c 1.0, CHCl3)
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Calcitroic acid: CTA methyl ester (0.52g, 1.33mmol) was dissolved
OH
O
H

in a solution of 10% NaOH in 9:1 MeOH:H2O (25mL) and stirred at
room temperature for two hours. When all starting material had
dropped to baseline by TLC, the reaction was neutralized with

HO

OH

concentrated HCl to ~pH 7. Excess MeOH was evaporated under

reduced pressure. The reaction was then diluted with H2O (25mL), acidified with concentrated
HCl to pH 1, and extracted with EtOAc (3 x 30mL). The combined organic layers were washed
with brine (25mL), dried over MgSO4, concentrated, and purified by column chromatography
(EtOAc) to yield calcitroic acid (CTA) (0.40g, 80%) as a yellow solid; Rf 0.14 (EtOAc); 1H-NMR
(500MHz, CDCl3) δ 0.60 (s, 3H), 1.06 (d, J = 6.5 Hz, 3H), 1.30-1.41 (m, 3H), 1.48-1.61 (m, 3H),
1.67-1.76 (m, 3H), 1.86-1.98 (m, 4H), 1.98-2.12 (m, 4H), 2.34 (dd, J = 13.0, 6.5 Hz, 1H), 2.50 (dd, J
= 15.0, 3.5 Hz, 1H), 2.62 (dd, J = 13.5, 3.2 Hz, 1H), 2.85 (dd, J = 13.6, 4.6 Hz, 1H), 4.26 (m, 1H),
4.46 (dd, J = 4.2, 7.6, 1H), 5.02 (s, 1H), 5.35 (s, 1H), 6.04 (d, J = 11.2 Hz, 1H), 6.39 (d, J = 11.2 Hz,
1H); 13C-NMR: (125MHz, CDCl3) δ 12.0, 19.7, 22.2, 23.5, 27.6, 29.0, 33.9, 40.3, 41.1, 42.8, 45.2,
45.9, 56.2, 56.3, 66.9, 70.8, 111.9, 117.2, 124.9, 133.1, 142.7, 147.6, 178.4; m/z calculated for
C23H34O4 373.2373 [M + H]—, found 373.2335; [𝛼]25
𝐷 = — 6.0 (c 1.0, CHCl3)
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O-silylated calcioic acid methyl ester: A solution of nO
O
H

butyllithium (1.6 M in hexanes, 0.55mL, 0.565mmol) was added
dropwise to a solution of calcioic acid A-ring phosphine oxide
(500mg, 0.715mmol, dried over 3Å molecular sieves in 3 ml

TBSO

THF overnight) at -78°C using freshly dried 3Å molecular sieves.

The solution turned deep red and was stirred for an hour at -78°C. Raising the solution out of the
bath briefly deepened the red color and ensured that the deprotonation was complete. The
solution was returned to the bath and C,D-ring ketone (147mg, 0.376mmol, dried over 3Å
molecular sieves in 2 ml THF overnight) was added dropwise. The solution was stirred for 5 hours
at -78°C and allowed to come to room temperature. The reaction mixture was then quenched
with 10mL water, diluted with TBME, and extracted (TBME, 2x50mL). Combined organic layers
were washed with brine, dried over MgSO4, and concentrated. The crude product was purified
by column chromatography (EtoAc: Hex 5:95) to yield O-silylated calcioic acid methyl ester as a
white crystalline solid (117mg, 41%); Rf 0.62 (EtOAc: Hex 1:9); 1H-NMR (500MHz, CDCl3) δ 0.060.10 (m, 6H), 0.60 (s, 2H), 0.90 (s, 9H), 1.00 (d, J = 4.0 Hz, 2H), 1.26-1.37 (m, 3H), 1.48-1.62 (m,
4H), 1.63-1.74 (m, 2H), 1.83-1.79 (m, 3H), 1.98-2.07 (m, 3H), 2.07-2.16 (m, 1H), 2.21-2.29 (m,
1H), 2.35-2.41 (m, 1H), 2.41-2.50 (m, 2H), 2.81-2.88 (m, 1H), 3.68 (s, 3H), 3.79-3.87 (m, 1H), 4.79
(s, 1H), 5.02 (s, 1H), 6.03 (d, J = 10.0 Hz, 1H), 6.17 (d, J = 10.0, 1H); 13C-NMR: (125MHz, CDCl3) δ 4.6, -4.5, 12.1, 18.2, 19.7, 22.2, 23.4, 25.9 (4C), 27.7, 28.8, 32.8, 34.1, 36.4, 40.4, 41.4, 45.8, 46.9,
51.4, 56.3 (2C), 70.6, 112.2, 118.0, 121.3, 136.6, 141.0, 145.4, 174.0; m/z calculated for
C30H50O3Si 487.3602 [M + H]+, found 487.3542; [𝛼]25
𝐷 = + 61.0 (c 1.0, CHCl3)
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Calcioic acid methyl ester: To a stirred solution of O-silylated
O
O
H

calcioic acid methyl ester (79mg, 0.16mmol) in dry THF (7mL),
tetrabutylammonium fluoride (1M in THF, 1.6mL, 1.6mmol) was
added. The reaction was stirred at room temperature overnight,

HO

then quenched with saturated NH4Cl solution (10mL). The mixture

was extracted with EtOAc (3x20mL) and the combined organic layers were washed with brine
(30mL), dried over MgSO4, concentrated, and purified by column chromatography (EtOAc: Hex
3:7) to yield the calcioic acid methyl ester as a clear oil (55mg, 91%); Rf 0.16 (EtOAc: Hex 1:3); 1HNMR (500MHz, CDCl3) δ 0.59 (s, 3H), 1.00 (d, J = 6.5 Hz, 3H), 1.28-1.36 (m, 4H), 1.49-1.58 (m,
3H), 1.64-1.71 (m, 3H), 1.84-1.98 (m, 4H), 1.98-2.04 (m, 3H), 2.15-2.22 (m, 1H), 2.26-2.32 (m,
1H), 2.26-2.32 (m, 1H), 2.38-2.48 (m, 2H), 2.56-2.61 (m, 1H), 2.81-2.87 (m, 1H), 3.68 (s, 3H),
3.92-3.98 (m, 1H), 4.82-4.83 (m, 1H), 5.05-5.07 (m, 1H), 6.04 (d, J = 11.2, 1H), 6.24 (d, J = 11.2,
1H); 13C-NMR: (125MHz, CDCl3) δ 12.0, 19.7, 22.2, 23.5, 27.6, 28.9, 32.0, 34.1, 35.2, 40.4, 41.4,
45.9, 46.0, 51.4, 56.2, 56.3, 69.2, 112.4, 117.8, 122.3, 135.4, 141.7, 145.1, 174.0; m/z calculated
for C24H36O3 373.2737 [M + H]+, found 373.2664; [𝛼]25
𝐷 = + 18.0 (c 1.0, MeOH)
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Calcioic acid: To a stirred solution of calcioic acid methyl ester
OH
O
H

(44mg, 0.12mmol) in ethanol (1.5mL) was added 1mL of 10%
aqueous NaOH. After disappearance of starting material by TLC
(around 1 hr), the reaction was neutralized with concentrated HCl

HO

to ~pH 7. Excess MeOH was evaporated off under reduced

pressure. The reaction was then diluted with H2O (25mL), acidified with concentrated HCl to pH
1, and extracted with EtOAc (3x5mL). The organic layers were washed with brine (5mL), dried
over MgSO4, concentrated, and purified by column chromatography (EtOAc : Hex 4 : 1) to yield
calcioic acid (25mg, 59%) as a white powder; Rf 0.53 (EtOAc); 1H-NMR (500MHz, CDCl3) δ 0.61 (s,
3H), 1.06 (d, J = 6.5 Hz, 3H), 1.30-1.40 (m, 4H), 1.50-1.61 (m, 3H), 1.65-1.74 (m, 3H), 1.86-1.99
(m, 4H), 1.99-2.10 (m, 3H), 2.17-2.23 (m, 1H), 2.30 (dd, J = 12.8, 5.5 Hz, 1H), 2.39-2.46 (m, 1H),
2.51 (dd, J = 14.9, 3.0 Hz, 1H), 2.57-2.63 (m, 1H), 2.82-2.88 (m, 1H), 3.94-4.00 (m, 1H), 4.84 (s,
1H), 5.07 (s, 1H), 6.06 (d, J = 10 Hz, 1H), 6.25 (d, J = 10 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ
12.02, 19.66, 22.20, 23.46, 27.66, 28.93, 31.95, 33.93, 35.14, 40.37, 41.19, 45.87, 45.88, 56.16,
56.27, 69.28, 112.49, 117.76, 122.32, 135.36, 141.71, 145.06, 178.96; m/z calculated for
C23H34O3 359.2581 [M + H]+, found 359.2524; [𝛼]25
𝐷 = —17.0 (c 1.0, CHCl3)
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1.7 Biological Characterization of Calcitroic Acid

Background
When DeLuca et al. isolated and characterized CTA, they also determined the affinity of
CTA for VDR and the vitamin D binding protein, which was 6.8μM and 10μM, respectively.
Applying mouse models in 1981, they observed some calcification of the epiphyseal plate of rats
maintained on a low phosphorus diet after a 7 day, 50ng/animal subcutaneous CTA treatment,
albeit 3 times less than what occurred with 5ng/animal treatment with calcitriol.92 Because of
the relative low affinity for CTA towards VDR, further investigations were not conducted.
In vitro investigations conducted a decade later using a luciferase assay under control of a
mouse osteopontin vitamin D response element (VDRE) in melanoma epithelial cells found that
at 20nM, CTA gene transcription was signiﬁcantly upregulated in comparison to other 25-hydoxy
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vitamin D3 metabolites.100 Similar results were observed with a luciferase transcription assay
using a CYP24A1 promoter VDRE.101 However, at 20nM CTA, no induction of the CYP24A1 gene
in HaCaT cells (immortalized keratinocyte) was observed when incubated for 4 hours or 24
hours.
Recently, the Arnold lab showed that while CTA was inactive in promoting the
recruitment of SRC2-3 to VDR, it was able to inhibit this interaction with an IC50 of 6.12 ± 2.1 μM
in the presence of calcitriol. Using a two-hybrid assay to investigate the interaction between VDR
and coregulator SRC-1, we have shown that CTA
promoted this interaction with an EC50 of 0.85 ± 0.33
μM but only 55% efficacy was achieved in
comparison to 20nM calcitriol. Thus, from these
initial results we can conclude that CTA behaves like
a partial VDR agonist. Further transcription assays
using DU145 prostate cancer cells demonstrated that
CTA induced VDR target gene CYP24A1 9-fold at
7.5μM (see Figure 16). Also in this case, the

Figure 16: CYP24A1 upregulation by synthetic phase 2
metabolites of lithocholic acid, LCA, and CTA (7.5μM) in
DU145 prostate cancer cells, with 1,25(OH)2D3 (20nM) as
a positive control and DMSO at a negative control.

induction was significantly lower than calcitriol at
20nM.
It is known that VDR regulates expression of CYP24A1102 in addition to CYP27B1103 in
order to regulate the formation and catabolism of calcitriol. It also regulates CYP3A4,104
CYP19A1,105 and CYP1A1106 as a xenobiotic sensor similar to the pregnane X receptor (PXR) and
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constitutive androstane receptor (CAR).107 Thus, vitamin D metabolites including CTA might play
a role in detoxification by interacting with VDR and taking part in the regulation of several
metabolic enzymes.
The synthesis of CTA enabled us to generate large quantities of CTA and to compare its
properties to that of previously purchased CTA.
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Interaction with VDR using fluorescence polarization
Fluorescence polarization (FP) is a fluorescence-based detection method that enables us
to differentiate between the molecular sizes of fluorescent complexes using monochromatic
polarized light. Small fluorescent compounds depolarize monochromatic emitted light due to
their fast rotation in solution; however, fluorescent compound-protein complexes have a low
tendency to depolarize light due to their slow tumbling in solution. For this competition assay we
are using a fluorescent peptide that is derived from VDR coactivator SRC2-3 and recombinant
expressed VDR-LBD and synthetic agonist LG190178. For this experiment, protein, peptide, and
LG190178 are incubated in the presence of different concentrations of CTA and CTA methyl ester
(Figure 17).

Calcitroic Acid

Calcitroic Acid Methyl Ester

Figure 17: Modulation of binding of SRC2-3 to VDR-LBD in presence of LG190178 as a function of displacement by CTA (A)
and CTA methyl ester (B).

61

Interaction with other nuclear receptors using a fluorescence polarization assay
After confirming that CTA binds to VDR, it is important to verify that this interaction is
specific to VDR among other nuclear receptors (NR). To this end, FP data was collected for the
binding of CTA to several other nuclear receptors including the androgen receptor, estrogen
receptor β, retinoid X receptor α, thyroid hormone receptor α, thyroid hormone receptor β, and
peroxisome proliferator-activated receptor γ (Figure 18).

Figure 18: Other nuclear receptors and their fluorescently labeled peptide sequences did not depolarize light in the presence of
CTA, providing evidence that CTA’s binding to VDR is specific.

For all assays, recombinantly expressed NR-LBDs were incubated with the corresponding
labeled coactivator peptide in the presence of different concentrations of CTA. All six nuclear
receptor assays did not show any change of FP. Thus, we can conclude that among the nuclear
receptors tested, CTA binding to VDR is specific.
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Interaction with VDR using x-ray crystallography
CTA was sent to collaborator Natacha Rochel, who generated

A

crystals of CTA bound to both a human and zebrafish recombinant
VDR-LBD. The protein was concentrated using Amicon ulta-30
(Millipore) to 3-7mg/mL and incubated with 2x excess of CTA and 3x

B

excess of coactivator peptide. Crystallization experiments occurred at
48°C. Crystals of hVDR complexed with CTA were obtained from a
solution containing 0.2M

Figure 22: Protein crystals of
(A) human LBD-VDR and (B)
zebrafish LBD-VDR

ammonium sulfate, 2.7M sodium formate, and 0.1M
PIPES (pH 7.0) (Figure 22A). Crystals of zVDR
complexed to CTA were obtained from a solution
containing 1.8M LiSO4 and 0.1M Mes (pH 6.0) (Figure
Figure 19: Stick-figure overlays of calcitriol (cyan)
and CTA (yellow) within the binding pocket of VDR.

22B). Protein crystals were mounted in a fiber loop

Figure 21: CTA in the binding pocket of zVDR LBD. The two OH
residues on the A-ring (lower left, red) are anchored by
donor/acceptor interactions with Tyr, Ser, and Arg residues,
while the acid function (upper right, red) interacts with histidine.

Figure 20: Protein-ligand interactions between CTA and
VDR. Green arrows indicate side-chain
donation/acceptance.
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and flash-cooled under nitrogen flux after cryo-protection with 20% glycerol. X-ray data has been
collected from the crystals followed by homology modeling. Overlaying of CTA with calcitriol
(Figure 19) visualizes the same binding mode of CTA and calcitriol. CTA forms several
donor/acceptor interactions with VDR. Serine 306 and tyrosine 175 interact with the 3-OH of
CTA, serine 265 and arginine 302 interact with 1-OH of CTA (Figure 23B), and histidine 423
interacts with the acid functionality of CTA (Figure 23A). The hydrophobic central ring structure
of CTA aligns well with the hydrophobic side chains present in the center of the VDR binding
pocket (Figure 21).

A
B

Figure 23: Detailed view of donor/acceptor interactions. (A) The acid functionality on CTA’s side chain interacts through
solvent contact with His 423. (B) On the other end of the molecule and binding pocket, the two hydroxyl groups make both
donor and acceptor contacts with Ser 306, Tyr 175, Ser 265, and Arg 302.
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Interaction with other nuclear receptors using a FRET-based assay
Fluorescence resonance energy transfer, or FRET, is a phenomenon where two lightsensitive chromophores situated within a certain distance of each other can transfer energy from
an exited state in the donor chromophore to the acceptor chromophore. Because the
wavelength used to excite the donor chromophore is different from the emission wavelength of
the acceptor chromophore, there is very low background radiation. Because FRET emission only
occurs when donor and acceptor chromophores are very close together and is proportional to
the sixth power of the distance between them, FRET is extremely sensitive to changes in distance
between the two. This makes the use of FRET technology for measuring binding very useful. The
recently developed BODIPY FL vindoline108 is a fluorescent FRET probe specific to PXR. A terbium
labeled anti-GST antibody is used to enable time resolved FRET by taking advantage of the
persistent fluorescence of lanthanides. Both PXR-LBD and CAR-LBD were generated with a GST
tag. The displacement of the probe by compounds that bind to the LBD of PXR reduce the FRET
signal, allowing for accurate assessment of PXR‒ligand inhibition. A similar principle was used for

A

B

Figure 24: (A) The PXR-BODIPY FL vindoline interaction was not inhibited in the presence of CTA. (B) The CAR-PGC1α
interaction was not inhibited in the presence of CTA.
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the FRET assay for the constitutive androstane receptor (CAR). However, in this case CAR-LBD was
incubated with a labeled coactivator PGC1α,109 which will bind CAR in the presence of an agonist
such as CITCO. When PXR-BODIPY FL vindoline was treated with CTA (Figure 24A) or when CARPGC1α was treated with CTA (Figure 24B), no inhibition of the FRET interaction took place,
providing further evidence that CTA does not participate in binding with PXR and CAR.
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Interaction with VDR using a transcription assay
With the confirmation from these protein assays that CTA did indeed bind specifically to
VDR, we began cell-based assays to determine more about CTA’s cell permeability and biological
relevance. A transcription assay uses plasmids that are transfected into cells (HEK293T) to enable
the generation of promoter-specific luciferase. For our assay, a cytomegalovirus promoter
causes overexpression of VDR, and the reporter plasmid’s luciferase gene is under control of a
CYP24A1 promoter. Thus, in the presence of an agonist, activated overexpressed VDR recognizes
the CYP24A1 VDRE and recruits RNA polymerase to transcribe the luciferase reporter gene. The
bioluminescence of the generated enzyme in the presence of substrate (luciferin) is directly
proportional to the amount of VDR-mediated transcription.

Figure 25: Combined dose response curves showing partial agonistic
activity (teal) and competitive inhibition in the presence of calcitriol
(pink) of CTA with VDR.

Dr. Teske showed for the first time that CTA behaves like a partial agonist in cells (Figure
25). In the presence of 10nM calcitriol, increasing the concentration of CTA will reduce the level
of transcription as low as 20% at concentrations higher than 100μM. The IC50 for this inhibition is
3.2 ± 2.4 μM. In the absence of calcitriol, CTA is able to activate VDR-mediated transcription to
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up to 20% of calcitriol transcriptional activity at 10nM with an EC50 of 2.5 ± 1.0 μM. Thus,
interestingly, CTA inhibits the binding of calcitriol, but it also acts as a partial agonist at nearly the
same concentration.
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Interaction with other nuclear receptors using transcription assays
The transcriptional activity of other nuclear receptors in the presence of CTA was
assessed by Prof. Merk’s laboratory (Goethe University Frankfurt). In their assays, plasmids
bearing NR-LBDs fused to a GAL4 DNA binding domain and a luciferase reporter with a UAS
promoter site are used. Cell were transfected overnight and treated with different concentration
of CTA (Figure 26).

A

B

C

D

Figure 26: Transcriptional activity was absent in assays of other nuclear receptors treated with CTA.

In all cases tested, positive control compounds upregulated transcription of each nuclear
receptor. However, CTA at different concentrations did not influence transcription. This result
provides further evidence that the binding of CTA is specific to VDR.
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Effect of CTA on macrophages
VDR is expressed in leukocytes, and calcitriol has been shown to modulate the immune
system and suppress immune responses.110 Macrophages, a type of phagocytic white blood cell
which engulfs and neutralizes foreign substances, are activated by infection and can maintain
inflammation.111 When stimulated to express an immune response, the activated M1 “killer”
macrophages release inflammatory cytokines like IL-1, IL-12, and IL-23 and induce iNOS, the nitric
oxide synthase involved in immune response. These transcriptional inflammatory products can
be quantified by qRT-PCR (Figure 27B). Nitric oxide (NO) release can be measured by the
formation of a brightly colored azo compound using a Griess assay (Figure 27A).112

A

B
Nitric Oxide Release

mRNA Upregulation

Figure 27: (A) Nitric oxide suppression as measured by Griess assay following stimulation with 150units/mL IFNγ and
50ng/mL LPS in RAW264.7 murine macrophages. 1,25(OH)2D3 and CTA exhibited a decrease in NO, along with the positive
control dexamethasone. (B) Downregulation of mRNA of inflammatory species in the presence of CTA and calcitriol, along
with positive control dexamethasone.
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To investigate whether CTA in addition to calcitriol can reduce inflammation, rat
macrophages (RAW264.7, ATCC TIB-71) were stimulated with 150units/mL IFNγ and 50ng/mL LPS
and dosed with calcitriol (20nM) and CTA (20μM) using DMSO (vehicle) and dexamethasone as
negative and positive controls, respectively. The supernatant media from these cells was used for
the Griess assay after 18 hours at 37°C, while the cells were harvested and their mRNA isolated.
Figure 27a shows a strong elevation of NO when cells were treated with IFNg/LPS and vehicle
DMSO.
Interestingly, calcitriol, CTA and dexamethasone reduced NO formation, although at
different concentrations. Similarly, mRNA of iNOS and IL-1b were downregulated by calcitriol,
CTA, and dexamethasone. This is consistent with our hypothesis that CTA interacts with VDR and
can regulate transcription.
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Effect of CTA on intestinal epithelial cells
Starting with colon cancer (Caco2) cells as a
preliminary model of the intestinal barrier, cells were
treated with CTA along with LCA (a known weak ligand of
VDR that can induce gene expression in the ileum113) with
DMSO and calcitriol as negative and positive controls,
respectively. We monitored the upregulation of CYP3A4
mRNA, along with that of several other CYP genes known

Figure 28: CYP3A4 upregulation by CTA (6μM) in
Caco2 cells. DMSO is a negative control. No
upregulation of other CYP mRNA was seen under
these conditions.

to be mediated by VDR (CYP2B6, CYP2C9).114 We observed specific upregulation of CYP3A4
mRNA by CTA but not that of other VDR-mediated enzymes CYP2B6 and CYP2C9 (Figure 28).
The much slower-growing normal human
intestinal epithelial cell line (HIEC-6) derived from
crypt cells was then purchased and cultured. In the
process of seeking out a better primer for CYP3A4,
we made an interesting discovery. When running an
agarose gel to ensure the selectivity of our CYP24A1
primers, calcitriol upregulated both the 317 kDa and
Figure 29: Gel of CYP3A4 primer, which is
differentially upregulated by CTA and calcitriol.

the 119 kDa splice variants of CYP24A1, which was
expected. However, CTA preferentially upregulated

the 317 kDa variant, with no 119 kDa splice variant seen (Figure 29). This was repeated several
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times with the same result. Investigating this surprising and specific difference may be a target of
future studies.

A

B

Figure 30: Upregulation by CTA and lithocholic acid (both 10μM) in HIEC6 human normal intestinal epithelial cells, with
1,25(OH)2D3 (20nM) as a positive control and DMSO at a negative control, against CYP3A4 (A) and CYP24A1 (B).

mRNA quantification was achieved by qRT-PCR (Figure 30). We observed that calcitriol at
20nM highly upregulated both CYP24A1 and CYP3A4 in HIEC6 cells. In comparison to 10μM LCA,
10μM CTA resulted in a more pronounced transcription of both CYP24A1 and CYP3A4, whereas
LCA induced no significant transcription. This evidence furthers the hypothesis that CTA may play
an integral part in detoxification by elevating CYP3A4 levels, an enzyme which is known to
metabolize LCA in the intestines.115
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Stability of CTA in the presence of P450 enzymes
It has been established that CYP3A4 plays a role in the hydroxylation of calcitriol as part of
its metabolic breakdown in intestines and liver.116 We investigated the stability of both CTA and
calcitriol in human liver microsomes (HLM) in order to determine the stability of CTA in the
presence of P450 enzymes including CYP3A4. Therefore, HLM were incubated in the presence of
CTA and aliquots were taken at specific time intervals. The concentrations of CTA were
determined by LCMS-MS and presented as their natural logarithm vs. time (Figure 31).

A

B

C

Figure 31: Microsomal digestion of CTA (A), calcitriol (B), and both CTA and calcitriol (C).

While we saw the expected breakdown of calcitriol under these conditions, we did not
observe metabolism of CTA during a period of 2 hours. Calcitriol exhibited a half-life of around
two hours. This experiment confirms that CTA is not further changed through phase I
metabolism. In order to investigate if CTA inhibits P450 enzymes, calcitriol was incubated in the
presence of CTA (Figure 31C). Because the half-life of calcitriol is not changing whether CTA is
present of not, we can conclude that CTA is not inhibiting P450 enzyme activity.
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Discussion
The biological data collected on CTA indicates that CTA is not the inactive metabolic
byproduct it had long been assumed to be. Binding data show that CTA binds specifically to VDR
among other nuclear receptors. X-ray crystallography confirmed this interaction and shows that
CTA adopts the same binding mode as calcitriol.
Cell-based assays demonstrate that CTA is cell membrane-permeable and inhibits the
interaction between VDR and calcitriol. However, the inhibition is partial (80%), because CTA is
also able to activate VDR-mediated transcription with an efficacy of 20%. Because both equilibria
occur at the same concentration, CTA can be described a partial agonist/antagonist.
When metabolism to CTA occurs in the kidney it can lead to urinary excretion; however,
phase II metabolism conjugation in the liver could lead to intestinal secretion of conjugated
vitamin D metabolites as bile. In the intestines, bacteria and intestinal cells can reverse this
process, which would liberate vitamin D metabolites to be reabsorbed and contribute to
enterohepatic circulation. Evidence already suggests that bile carries large quantities of vitamin
D metabolites, which were isolated and characterized during the last 40 years.69 Our work is
focused on the physiological activity of CTA in the intestine.
One important cell type mediating the immune response in the intestine are
macrophages. It has been reported that macrophages mediate diseases such as inflammatory
bowel disease.117 We were able to show for rat macrophages that CTA in addition to calcitriol can
significantly decrease inflammation based on the reduction of two inflammation markers, IL-1b
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and iNOS, in the presence of IFNγ/LPS. Thus, we believe that CTA is acting as a natural antiinflammatory molecule.
Another important intestinal cell type are epithelial cells that are part of the
gastrointestinal wall. These cells are known to express P450 enzymes to combat xenobiotic
toxicity.118 We have shown that CTA and calcitriol were able to upregulate the transcription of
these enzymes in vitro. Furthermore, we observed that the regulation of CYP24A1 differs
between CTA and calcitriol. Further investigations are necessary to investigate this phenomenon.
In conclusion, we are presenting compelling evidence for the link between the
detoxification of the gut and VDR’s CTA-mediated activity. We believe that the water-soluble
metabolites of vitamin D that are secreted into the intestinal tract protect the colon from
inflammation-inducing accumulation of xenobiotics such as lithocholic acid by upregulation of
CYP3A4.85 Vitamin D has been shown to provide a noticeable amount of relief from symptoms in
IBD as well.119 The mechanism by which this relief takes place remains unknown, and these
results indicate that it could be mediated in part by CTA.
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Experimental Procedures:
Fluorescence Polarization Binding Assay Protocol
The FP assay buffer was prepared by adding 25mM PIPES (piperazine-N,N’-bis(ethanesulfonic
acid, Sigma-Aldrich), 50mM NaCl (Fisher), and 0.01% NP-40 detergent to 18.2MΩ water. The
buffer was filtered and adjusted to pH 6.75. To this was added 7.5nM of the coactivator peptide
SRC2-3 (CKKKENALLRYLLDKDDTKD) which had been labeled with cysteine-reactive AlexaFluor647.
To this solution was added 250nM of VDR-LBD, which had been expressed and purified as
reported previously.120 The VDR agonist LG190178, which had been synthesized previously
according to a published protocol,121-122 was added at a concentration of 600nM. A 10mM stock
of CTA in DMSO was serially diluted (1:2) in a 384-well plate (Corning, CLS3702). To a 384-well
black polystyrene microplate (Corning, CLS3658), 20μL of the prepared VDR-LBD assay solution
was dispensed to test against the CTA serial dilution. Using the Tecan Freedom EVO liquid handler
system and a 100nL pin tool (V&P Scientific), a total of 200nL of each CTA concentration was
transferred in quadruplicate to the 20μL assay solution for a final maximum concentration of
100μM CTA. Following incubation for 1 hour, fluorescence polarization was detected at an
excitation/emission wavelength of 635/685 nm using the Tecan Infinite M1000 plate reader. The
result showed CTA binding at an IC50 of 8.5μM. To verify specificity, CTA was investigated with
other nuclear receptors and their respective agonists and coactivators (thyroid receptor α LBD
(2μM)/Texas Red-labeled SRC2-2 (7nM)/triiodothyronine (1μM); thyroid receptor β LBD
(0.8μM)/Texas Red-labeled SRC2-2 (7nM)/triiodothyronine (1μM); peroxisome proliferatoractivated receptor γ (5μM)/Texas Red-labeled DRIP2 (7nM)/rosiglitazone (5μM); androgen
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receptor LBD (5μM)/Alexa Fluor 647-labeled SRC2-3 (7nM)/dihydrotestosterone (10nM);
estrogen receptor β LBD (5μM)/Texas Red-labeled SRC2-2 (7nM)/estradiol (20nM)).

Transcription Assay Protocol
Human embryonic kidney (HEK293, ATCC CRL-3249) T cells were cultured in DMEM/High
Glucose (Hyclone, #SH3024301) with non-essential amino acids (Hyclone, #SH30238.01), 10 mM
HEPES (Hyclone, #SH302237.01), 5 x 106 units of penicillin and streptomycin (Hyclone,
#SV30010), and 10% of FBS (Gibco, #10082147). Transfection was carried out with 70-80%
confluent cells. For VDR transfection, 2 mL of untreated DMEM/High Glucose media containing
0.7 μg of VDR-CMV plasmid, 16 μg of a CYP24A1-luciferase reporter gene, LipofectamineTM LTX
(75 μl, Life Technologies #15338020), and PLUSTM reagent (25 μl) was added to the flask. After
16 hours of incubation at 37oC with 5% CO2, the cells were harvested with 3mL of 0.05% Trypsin
(Hyclone, #SH3023601), added to 10mL of the assay buffer (DMEM/High Modified buffer
without phenol red, Hyclone #SH30284.01) and spun down for 2 minutes at 1000 rpm. The
media was removed and cells were resuspended in the DMEM assay media. Prior to adding cells
to sterile white, optical bottom 384-well plates, plates were treated with 20 μL per well of a
0.25% matrigel solution. To each well, 20μL of cells were added to yield a final concentration of
15,000 cells per well. The plates were then spun down for 2 minutes at 1000 rpm. After four
hours, plated cells were treated with 100 nL of compounds and controls which were added using
the EVO liquid handling system with a 100nL pin tool (V&P Scientific). Controls used with VDR
were 1,25(OH)2D3 (10 nM in DMSO, Endotherm) and DMSO. After 16 hours of incubation at 37oC
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with 5% CO2, 20μL of Bright-Glo™ Luciferase Assay Kit (transcription assay, Promega, Madison,
WI) were added and luminescence was read on the Tecan Infinite M1000 reader.

Transcription Assay (provided by Prof. Daniel Merk)
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), high glucose with
10% fetal calf serum (FCS), sodium pyruvate (1mM), penicillin (100U/mL), and streptomycin
(100μg/mL) at 37°C and 5% CO2. Twenty-four hours before transfection, HEK293T cells were
seeded in 96-well plates (3 × 104 cells/well). Before transfection, medium was changed to
OptiMEM without supplements. Transient transfection was carried out using Lipofectamine LTX
reagent (Invitrogen) according to the manufacturer’s protocol with pFR-Luc (Stratagene), pRLSV40 (Promega), and the corresponding Gal4-fusion nuclear receptor plasmid. Five hours after
transfection, medium was changed to OptiMEM supplemented with penicillin (100 U/mL),
streptomycin (100 μg/mL), and additionally containing 0.1% dimethyl sulfoxide (DMSO) and the
respective test compound or 0.1% DMSO alone as untreated control. Each concentration was
tested in duplicates and each experiment was repeated independently at least three times. After
overnight (14−16 h) incubation with the test compounds, the cells were assayed for luciferase
activity using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer’s
protocol. Luminescence was measured with an Infinite M200 luminometer (Tecan Deutschland
GmbH). Normalization of transfection efficiency and cell growth was done by division of firefly
luciferase data by Renilla luciferase data and multiplying the value by 1000 resulting in relative
light units (RLU). Fold activation was obtained by dividing the mean RLU of a test compound at a
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respective concentration by the mean RLU of the untreated control. Relative activation was
obtained by dividing the fold activation of a test compound at a respective concentration by the
fold activation of a respective reference agonist: RXRα: bexarotene (EC50: 33nM) LXRα/β:
T09021317 (EC50 ∼ 50nM); FXR: GW4064 (EC50 = 70nM). All hybrid assays were validated with
the above-mentioned reference agonists which yielded EC50 values in agreement with the
literature.

Griess Assay Immune Modulation Protocol
The murine macrophage cancer cell line RAW264.7 was cultured in DMEM (ATCC 30-2002) with
10% FBS. To initiate an immune response, cells were suspended at a cell density of 1x10 6
cells/mL and a control sample (3mL) was dispensed into a 6-well clear-bottomed sterile plate
with a lid (Corning 3516). The remaining suspended cells were then activated with interferon
gamma (IFNγ, 150units/mL) and lipopolysaccharide (LPS, 50ng/mL). Activated cells were
dispensed into the 6-well plate (3mL/well). Cells were then dosed with compounds of interest to
the following final concentrations: calcitriol (20nM), CTA (5μM, 20μM), with dexamethasone as a
positive control (10μM), and DMSO as a negative control. The plated cells were then allowed to
incubate for 18 hours. Following incubation, aliquots of the supernatant (80μL) from each 6-well
sample were taken in replicates of 8 and transferred to a 384-well clear-bottomed plate with a lid
(CLS3700). To each aliquot was added 10μL of sulfanilamide solution (Promega Griess Reagent
System, TB229). The covered plate was shaken briefly and incubated in the dark for 10 minutes.
Following this, 10μL of NED solution (Promega Griess Reagent System, TB229) was added to each
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aliquot. The plate was again shaken briefly and incubated in the dark for 10 minutes. The
absorbance of the plate was then read on the Tecan Infinite M1000 plate reader (530nm).

Quantitative Real Time Polymerase Chain Reaction Protocol
The human colon cancer cell line Caco2 (ATCC HTB-37) or the human normal intestinal epithelial
cell line HIEC-6 (ATCC CRL-3266) were purchased and cultured according to ATCC’s listed method.
The cells were harvested with 0.25% Trypsin and then were plated (3mL) in a 6-well clearbottomed sterile plate with lid (Corning 3516) at a concentration of 1x106 cells/mL. The plate was
incubated overnight at 37°C for the cells to settle and adhere to the plate. Cells were then dosed
with compounds of interest to the following final concentrations: calcitriol (20nM), CTA (20μM),
lithocholic acid (20μM), and DMSO as a negative control. The plate was incubated for 24 hours at
37°C. The cell media was then removed, the cells rinsed briefly with PBS, and then harvested
with 300μL of 0.25% Trypsin. The Trypsin was then diluted when cells were free by addition of
700μL of normal media. The suspended cells were then transferred to Eppendorf 1.5mL tubes.
The cells were spun down at 1800rpm for 5 minutes to form a pellet. The media was removed
and the cells disrupted by adding 350μL of 1% β-mercaptoethanol in Buffer RLT (from Qiagen
RNeasy Mini Kit 74104) to each and vortexing. The lysate was pipetted directly onto QIAshredder
spin columns (Qiagen 79654) in a 2mL collection tube and centrifuged for 2 minutes at 1800rpm.
To the homogenized lysate 350μL of 70% ethanol was added. The 700μL of solution was
transferred to the RNeasy spin column and spun down at 1800rpm for 15 seconds. Flow-throughs
were discarded and the column was washed sequentially with 700μL Buffer RW1, 500μL Buffer
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RPE x2, and then the RNA eluted into a 1.5mL collection tube with 50μL of The RNA Storage
Solution (Ambion, AM7001). The amount of RNA collected and its purity was measured by
measuring UV signal at 260nm with the Tecan Infinite M1000. Samples of RNA were then taken
and added to a solution containing forward and reverse primers for the sequences of interest
along with the calculated amounts of quantifastRT, SYBR Green solution, and RNase-free water.
Primers used for various experiments included the GAPDH housekeeping gene (forward: 5’ACCACAGTCCATGCCATCAC-3’ reverse: 5’-TCCACCACCCTGTTGCTGTA-3’), CYP3A4_1 (forward: 5’CCTACATATACACACCCTTTGGAAG-3’ reverse: 5’-GGTTGAAGAAGTCCTCCTAAGCT-3’)(Blast see
below), CYP3A4_2: (forward: 5’-CACAAACCGGAGGCCTTTTG-3’ reverse: 5’ATCCATGCTGTAGGCCCCAA-3’) (Blast see below) CYP2B6 (forward: 5’GGCCATACGGGAGGCCCTTG-3’ reverse: 5’-AGGGCCCCTTGGATTTCC-3’), and CYP2C9 (forward: 5’TCCTATCATTGATTACTTCCCG-3’ reverse: 5’-AACTGCAGTGTTTTCCAAGC-3’). Replicates were
pipetted into a 96-well PCR plate (Eppendorf 951022003). The program used on the thermal
cycling machine (Eppendorf AG22331 Hamburg Mastercycler) was 5 minutes at 95°C (initial
activation step), and then cycling through 10 seconds at 95° C (denaturation step) and 30
seconds at 60°C (annealing step) for 50 cycles.
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Microsomal Stability Assay Protocol
8µL of 1mM test compound (at a final concentration of 20µM) in DMSO was pre-incubated at
37°C for five minutes on a digital heating shaking dry bath (Fischer scientific, Pittsburgh, PA) in a
mixture containing 274µL of water, 80µL of phosphate buffer (0.5M, pH 7.4), 20µL of NADPH
Regenerating System Solution A (BD Bioscience, San Jose, CA) and 4µL of NADPH Regenerating
System Solution B (BD Bioscience, San Jose, CA) in a total volume of 391.2µL. Following preincubation, the reaction was initiated by addition of 8.8µL of either human liver microsomes (BD
Gentest, San Jose, CA) or mouse liver microsomes (Life technologies, Rockford, IL), at a protein
concentration of 0.5mg/mL. Aliquots of 50µL were taken at time intervals of 0 (no microsomes),
10, 20, 40, 60, 90 and 120 minutes (calcitriol) or 0 (no microsomes), 20, 40, 60, 80, 100, and 120
minutes (CTA). Each aliquot was added to 100µL of cold methanol solution containing 450nM of
4,5-diphenylimidazole (4,5–DPI) (for a final concentration of 300-nM) as internal standard in a 96
well plate. The quenched samples were transferred to a filter plate and vacuum filtrated. The
filtrate was diluted 10-fold and analyzed subsequently by LC-MS/MS with the Shimadzu LCMS
8040 instrument. CTA and calcitriol were monitored under positive mode by Shimadzu 8040
triple quadrupole mass analyzer (Shimadzu, Kyoto, Japan) with electrospray ionization (ESI). The
following transitions are monitored in multiple reaction monitoring (MRM) mode. Transitions for
calcitriol were m/z 434.30 > 399.35, 434.30 > 381.35, 434.30 > 363.35, and 434.30 > 227.15.
Transitions for CTA were m/z 375.35 > m/z 357.25, m/z 375.35 > m/z 339.25, and m/z 375.35>
m/z 121.15. Transition pairs for verapamil are m/z 455.60 > m/z 303.20, m/z 455.60 > m/z
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165.20, and m/z 455.60 > m/z 150.00. Collision energy is optimized for each transition to obtain
optimal sensitivity. The mass spectrometer was operated with the heat block temperature of
400°C, drying gas flow of 15L/min, desolvation line temperature of 250°C, nebulizing gas flow of
1.5L/min, and both needle and interface voltages of 4.5kV.
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1.8 The Phase II Metabolism of Calcitroic Acid

Two principal phases of metabolism exist in living organisms: Phase I (oxidation,
reduction and hydrolysis) and Phase II (conjugation). Phase I metabolism has been introduced in
Chapter 1.3; it takes place predominately in the kidneys and liver and transforms vitamin D into
its metabolites, including both calcitriol and CTA.123 More broadly speaking, Phase I metabolism
uses various enzymes to convert xenobiotics in the bloodstream into corresponding metabolites
with increased solubility by unmasking polar functional groups or by adding new ones to the
existing molecule.124 Typically, the xenobiotic metabolite is less toxic and more easily excreted
through urine and bile. For pharmaceuticals, metabolism typically reduces their pharmacologic
activity.125 However, in some cases metabolism increases the physiological activity of certain
compounds.126 This has long been known to be the case for vitamin D, which does not interact
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with the vitamin D receptor; however, upon metabolism, calcitriol and several other metabolites
do.127
Phase II metabolism refers to the conjugation of compounds to polar molecules which is
meditated by enzymes in living organisms. Sometimes, the conjugation occurs at positions that
were generated by phase I metabolism through oxidation or unmasking, such as a hydroxyl
group.128 The addition of water-soluble functional groups increases the overall solubility of the
xenobiotic, and as a result it typically reduces toxicity and negates pharmacological activity.129
The enzymes involved in these transformations are typically associated with activated
coenzymes and transfer the polar compound from the cofactor to the xenobiotic species,
although in some cases the opposite occurs and the coenzyme associates with the xenobiotic,
transferring it onto the polar group in the presence of the transferase enzyme.128 Phase II
metabolism occurs in the canonical metabolic sites, the liver and kidneys, but also can occur in
other organs, such as the intestines, lungs, and skin.130
The phase II metabolites of vitamin D metabolic products have yet to be investigated. It is
surprising that despite the wealth of knowledge about vitamin D2 and D3 and the recognition
that their VDR activity occurs only after metabolism,131 only the phase I metabolites have been
the focus of research. To address this lack of knowledge, our group is investigating phase II
conjugates of vitamin D metabolites. Our first focus is on the final metabolite CTA because of its
stability, unique carboxylic acid functionality,7 and relative abundance in the body.5 While
conjugation in the kidney often leads to urinary excretion, the liver’s conjugation processes can
excrete vitamin D metabolites into the intestines as bile by way of the bile duct.132 We already
88

know that the bile is likely the location of the highest concentration of CTA, which nearly 40
years ago was isolated as its corresponding methyl ester.8 As such, we expect that conjugates of
vitamin D metabolites will likely be found there as well. It is known that bacteria in the gut can
reverse conjugations,133 leading to a likely scenario where the intestines are exposed to an
elevated concentration of unconjugated vitamin D metabolites, which in turn can be reabsorbed
and induce a physiological effect. We have shown that this phenomenon could have important
biological ramifications for CTA, which mediates multiple physiological effects, e.g. upregulation
of CYP3A4 in gut epithelia cells.4 This pharmacological effect is particularly important with
reference to lithocholic acid, the toxic bile acid which is known to be metabolized by P450
enzyme CYP3A4.134 The CYP3A4 gene is regulated transcriptionally by the vitamin D receptor.135
Interestingly, lithocholic acid interacts weakly with VDR and influences its own catabolism
through its induction of CYP3A4.136 Our hypothesis is thus that CTA, as a ligand interacting with
VDR in the gut, is aiding in the intestinal detoxification process and could thus reduce the
occurrences of colon cancer, ulcerative colitis, and Crohn’s disease.137
There are six phase II transformations: sulfation, glucuronidation, acetylation,
methylation, glutathione conjugation and amino acid conjugation. Of these, we investigated
sulfation, glucuronidation, and amino acid synthetic conjugation to CTA. Acetylation typically
forms less polar compounds and does not affect the type of oxygen-containing functional groups
found in CTA,138 so we excluded it along with methylating transformations.139 Glutathione
conjugation by contrast is actually the first step in the generation of a set of several conjugated
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metabolites.140 Because this transformation usually occurs with electrophilic groups not present
in CTA, we did not investigate this conjugate.
Sulfation, by contrast, is a very common enzymatic transformation that can occur with an
alcohol group to form the corresponding sulfate. In humans, four families of sulfotransferases
have been identified, nearly all of which use 3’-phosphoadenosine-5’-phosphosulfate (PAPS) as
their cofactor.141 Steroids are common substrates for sulfotransferases, producing sulfates such
as the estrogen sulfate conjugate.128 To investigate the sulfation of CTA in vivo, we synthesized
both the mono-sulfate and the di-sulfate CTA conjugates as standards for identifying sulfo-CTA
conjugates from tissues.
Glucuronidation is one of the most common Phase II metabolic transformations,
occurring in many different tissues including the liver, kidneys, and intestine. The transformation
produces more water-soluble carbohydrate metabolites.130 Glucuronidation involves the
conjugation of glucuronic acid, which is widely available as the enzyme cofactor uridine 5’diphosphate glucuronic acid (UDP-glucuronic acid). The enzymes responsible for this
transformation are UDP-glucuronosyltransferases, a large class of cytosolic membrane-bound
enzymes.142 Glucuronidation is arguably one of the most important processes in phase II
metabolism, being the major elimination pathway for common xenobioitics, drugs,
environmental toxins, and endogenous small molecules, e.g. steroids.130 We are currently
investigating if glucuronides of CTA are formed in vitro and in vivo.
We also synthesized the two amino acid conjugates of CTA which reflect the most
common phase II amino acid conjugates: glycine and taurine. Both conjugations can be formed
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in either liver or kidney. Conjugates generated in the liver are typically secreted as bile.143 The
process of amino acid conjugation occurs in two steps. First, the ligation of the xenobiotic to
acyl-CoA occurs by the corresponding ligase, followed by the formation of an amide bond with
glycine by the enzyme glycine N-acyltransferase, or in the case of taurine, by the taurine Nacyltransferase.144 In the case of CTA, it could be expected that these amino acid conjugates
would act as bile acids, secreted into the intestines where they could be de-conjugated by
microbes and reabsorbed.139
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1.9 Synthetic Strategy for the Production of Calcitroic Acid Conjugates

Synthesis of taurine CTA conjugate:
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OH
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In order to test out reaction conditions with a compound with similar characteristics and
reactivity to CTA but less precious and commercially available, I began experimenting with
taurine conjugation using the commercially available bile acid lithocholic acid (LCA). Initial
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experiments used the Dayal et al. method,145 which was touted to be quick and effective using a
conventional (non-scientific) microwave. If combining LCA, taurine, and EEDQ (coupling reagent)
in dry ethanol and triethylamine (base) and microwaving in a water bath sounds unlikely to work
to you, you would be right. After testing a few times using different setups, we moved on to a
more reasonable synthesis from Tserng involving the same reagents but DMF instead of ethanol
to increase solubility. The reaction was stirred at 90°C for 1 hour.146 The product was formed as
determined by TLC, but the suggested isolation procedure, which involves pouring into the
solution into a diethyl ether ice bath, would not be effective on the microscale on which we
would be synthesizing tauro-CTA. We instead took a page from the Dayal reaction and used
ethanol for the solvent, otherwise following the Tserng reaction conditions. This worked
perfectly. Switching from LCA to CTA after that successful reaction provided the corresponding
product with no further complications. After filtering of the insoluble leftover taurine, we could
simply dry off the ethanol. The reaction could then be taken up in a minimum amount of water
and the highly nonpolar byproducts extracted away with toluene. What remained was TEA and
product. After trying to remove the large amount of remaining TEA by several methods including
high vacuum, extraction, and azeotropic distillation to no success, we realized that it was forming
a strong ion-pairing with the sulfonate. Therefore, we used solid phase extraction (SPE) to
remove TEA by flushing the loaded crude product with a saturated sodium chloride solution
(brine) until the TEA eluted. The salt on the cartridge could then be washed away with DI water
and the product was eluted in 30% methanol in water. Upon evaporation under reduced
pressure, the brown Cl— taurine salt conjugate was isolated in high purity. The detailed
procedure can be found in the experimental procedure section.
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Synthesis of glycine CTA conjugate:

Initially, we attempted the synthesis of the glycine conjugate using LCA to test the
method previously established by Incerti et al.,147 which uses N-(3-dimethylaminopropyl)-N’ethylcarbodiimide hydrochloride (EDCI) as the coupling reagent and N-methyl morpholine
(NMM) as the base to attach O-methylated L-glycine to the LCA acid functionality by stirring in
DCM at room temperature overnight. This was followed by deprotection of the ester under basic
conditions. The procedure worked as expected for the LCA. However, the reaction failed when
we attempted it with CTA. CTA did not dissolve in DCM to the extent that the reaction could
proceed, and only trace amounts of product were recovered. We made further attempts in THF
and pyridine, which were also unsuccessful, before deciding we needed more than just solvent
changes.
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Therefore, we started with the O-Bis-silylated CTA and hydrolyzed it. This reaction was
simple and effective in methanol/water that was adjusted to properly dissolve the starting
material. NaOH was added up to 10% w/v, and the reaction stirred at room temperature for
three hours until it was complete. The mixture was evaporated, redissolved in water followed by
extraction with DCM giving the pure acid after evaporation.
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The O-Bis-silylated CTA was able to dissolve completely in DCM; however, very small
scale (1-2mg) reactions were not forming the anticipated amide. After experimenting with LCA
again, we discovered that the proportions of the reagents were very important: the ratios of
NMM, EDCI, and the glycine methyl ester needed to be 9:4:4 respectively. Thus, reactions with
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only a milligram or two of CTA and 40-80mg of the other materials would still form the ester
after one hour at room temperature as long as the proportions between the other reagents
were correct.
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The deprotection of the silyl groups, initially attempted with TBAF, was a clean reaction
by TLC, but it was impossible to separate the product from the leftover TBA. After several
attempts that included washing with NH4Cl to dissolve away the salt, extracting using many
different solvents, column chromatography, ion-exchange resin,148 precipitating as a
perchlorate,149 and using KF as an alternative F— source, we found an alternate TBS deprotection
method used by Nakabayashi et al.150, one of the world’s premier laboratories focused on the
synthesis of secosteroidal vitamin D analogues. Their group employed the use of
camphorsulfonic acid (CSA) to remove TBS groups in a speedy (~15 min) reaction in dry methanol
at room temperature. Of note is that running the reaction with stoichiometric amounts of CSA
was unsuccessful or at best very slow, and the product as it turns out degrades very quickly in
acid. However, with excess (6 eq) of CSA, the reaction was very quickly complete. The
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degradation problem was ameliorated by swiftly quenching the completed reaction with enough
NaHCO3 to neutralize the CSA, immediately concentrating it to get rid of the methanol, and then
extracting the product with EtOAc. Immediate column chromatography and concentration of
purified product gave the best yields.
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The hydrolysis to the glycine conjugate was a clean reaction, where the final precipitated
product was pure provided it was not left long in acid. The reaction in water and methanol with
up to 15% NaOH w/v was complete in 10 minutes. After evaporating off all methanol, the
residue was dissolved in a minimum amount of water in a small Eppendorf tube, and the pH was
adjusted HCl until the solution was just acidic (pH 1). The Eppendorf tube was quickly centrifuged
to collect the white, grainy precipitate, which was dried overnight under high vacuum. The
precipitate was then loaded on an SPE cartridge to remove salt impurities by washing with
water, then eluted in a gradient from water to methanol (product came off between 40-50%
methanol). Product was then quickly dried down, and purity was confirmed by NMR. The
detailed protocol can be found in the experimental section.
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Synthesis of bis-sulfate CTA conjugate:
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We used the sulfation method previously established in our lab, which had been used to
make the LCA-sulfate conjugate. After testing the reaction conditions with both LCA and
ergocalciferol, we tried the same method with CTA. In this reaction, H2SO4 and acetic anhydride
were lightly heated to dissolve everything in pyridine, and then CTA was added. The reaction was
complete after about ten minutes, and it was then cooled to 0°C, quenched with 25% NH4OH in
water, stirred for 15 minutes, filtered, and concentrated. The crude mixture was then loaded on
an SPE column, washed with pure water, and then eluted with up to 30% methanol in water. The
di-sulfonated CTA conjugate was pure by NMR, and no further purification was necessary.
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Synthesis of mono-sulfate CTA conjugate:
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In contrast to the bis-sulfated conjugate, very specific measurements are needed in this
reaction to maximize the amount of mono-sulfate produced and minimize the bis-sulfate
byproduct, which readily occurs with any sulfuric acid in excess of 1:1 proportions. As such, we
prepared a solution of 0.5M H2SO4/1.0M acetic anhydride in pyridine and combined it with CTA
to make a solution of 1:1:2 CTA:H2SO4:acetic anhydride proportions. No heat is necessary in this
reaction because the sulfuric acid is dilute enough to stay in solution at room temperature. The
reaction is complete within a half hour. Even with a 1:1 stoichiometry both mono and bissulfated CTA were formed. The completed reaction was quenched with 25% aqueous NH4OH,
concentrated, loaded onto an SPE cartridge, and eluted using an incremental gradient in order to
separate the bis-sulfate from the mono-sulfate. The bis-sulfate eluted up to 25% MeOH in water,
with the mono-sulfate eluting up to 35% MeOH in water.
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1.10 Characterization of Calcitroic Acid Conjugates

The CTA used in these syntheses was generated following the procedures described in
Chapter 1.6. All moisture and/or oxygen-sensitive reactions were carried out under a dry
nitrogen atmosphere. Reaction temperatures refer to the containing bath temperatures.
Reactions were monitored by thin-layer chromatography (TLC) using Merck 60 UV254 silica gel
plates. Visualization was performed with UV light, cerium molybdate general stain followed by
heating, and other methods as noted. Synthesized compounds were purified by normal phase
flash chromatography (SPI Biotage, silica gel 230-400 mesh) or solid phase extraction (Waters
Sep-Pak C18 6cc Vac cartridge) except where noted. Mass analysis was performed using a
Shimadzu 2020 LC-MS (single quadrupole) instrument and exact mass analysis was performed
using a Shimadzu LCMS-IT-TOF. NMR spectra were recorded on a Bruker Avance 500MHz

102

instrument with compounds dissolved in the specified deuterated solvent. Optical rotations were
recorded using Jasco DIP-370 Digital Polarimeter instrument in LCMS grade chloroform or
methanol.

Tauro calcitroic acid: To a stirred solution of CTA (45.6mg,
NH

0.123mmol) in ethanol (1.25mL) was added N-

O
H

SO3

-

ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (75mg,
0.30mmol), taurine (30mg, 0.24mmol), and triethylamine

HO

OH

(75μL, 0.54mmol). The reaction was refluxed for 1 hour,

then removed from heat and filtered. The filtrate was concentrated and the residue taken up
into a minimal amount of water (5mL), then extracted with toluene (2x5mL). The aqueous layer
was then loaded onto an 500mg Sep-Pak Vac 6cc C18 cartridge and eluted in a gradient from
brine to methanol (brine:MeOH 1:1). Fractions containing product were concentrated, then
desalted using a second cartridge (water:methanol 7:3) to yield tauro-calcitroic acid as a yellow
solid (20.4mg, 37%); Rf 0.14 (CHCl3 : MeOH 7 : 3); 1H-NMR (500MHz, CDCl3) δ 0.49 (s, 3H), 0.87
(d, J = 6.25 Hz, 3H), 1.21-1.32 (m, 3H), 1.34-1.53 (m, 4H), 1.57-1.68 (m, 2H), 1.72-1.96 (m, 7H),
1.96-2.02 (m, 1H), 2.22 (dd, J = 13.1, 7.6 Hz, 1H), 2.32-2.37 (m, 1H), 2.50-2.55 (m, 1H), 2.76-2.82
(m, 1H), 3.01 (t, J = 6.9 Hz, 2H), 3.50 (t, J = 6.9 Hz, 2H), 4.07-4.13 (m, 1H), 4.33-4.37 (m, 1H), 4.93
(s, 1H), 5.25 (s, 1H), 6.00 (d, J = 11.3 Hz, 1H), 6.40 (d, J = 11.3 Hz, 1H); 13C-NMR: (125MHz, CDCl3)
δ 11.2, 18.5, 21.7, 23.1, 27.2, 28.6, 34.4, 35.0, 39.8, 41.1, 43.1, 44.0, 45.9, 49.7, 55.8, 56.1, 66.3,
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70.5, 112.6, 116.7, 123.9, 134.4, 144.9, 146.5, 176.8; m/z calculated for C25H38NO6S 480.2340
[M]—, found 480.2333; [𝛼]25
𝐷 = + 0.70 (c 1.0, MeOH)
O-bis-silylated glyco calcitroic methyl ester: To a stirred solution
O

of O-bis-silylated CTA (93 mg, 0.15mmol), glycine methyl ester

O
NH
O
H

hydrochloride (43mg, 0.35mmol), and N- methyl morpholine
(87.5μL, 0.88mmol) in dry DCM (10mL) was added 1-ethyl-3-(3dimethylaminopropryl)carbodiimide (66mg, 0.35mmol). The

TBSO

OTBS

reaction was allowed to stir for two hours at room

temperature. The reaction mixture was quenched with 10mL of 2M HCl, extracted with DCM
(10mLx3), and the combined organic layers were washed with brine. The organic layers were
dried over MgSO4 and concentrated to the O-bis-silylated glyco calcitroic methyl ester (93mg,
90%) as a clear oil. No attempts were made to purify the product further: Rf 0.21 (DCM); 1H-NMR
(500MHz, CDCl3) δ 0.08 (s, 12H), 0.58 (s, 3H), 0.89 (s, 18H), 1.02 (d, J = 11.0 Hz, 3H), 1.30-1.40
(m, 3H), 1.44-1(m, 3H), 1.6-1.71 (m, 2H), 1.75-1.83 (m, 1H), 1.83-2.06 (6H), 2.23 (dd, J = 24.0,
12.5 Hz 1H), 2.42-2.52 (m, 2H), 2.79-2.88 (m, 1H), 3.78 (s, 3H), 4.08 (d, J = 8.5 Hz, 2H), 4.16-4.26
(m, 1H), 4.38 (dd, J = 10.5, 5.9 Hz, 1H), 4.87 (d, J = 3.7 Hz, 1H), 5.19 (d, J = 2.6 Hz, 1H), 5.94-6.07
(m, 2H), 6.25 (d, J = 18.8 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ –5.1, –4.8, –4.69, –4.67, 12.0,
18.1, 18.2, 19.5, 22.1, 23.4, 25.8 (3C), 25.9 (3C), 27.8, 28.8, 34.5, 40.5, 41.2, 43.7, 44.8, 45.9,
46.1, 52.3, 56.3, 56.5, 67.5, 72.1, 111.3, 118.1, 123.1, 135.2, 140.6, 148.3, 170.6, 173.1; m/z
calculated for C38H67NO5Si2 674.4631 [M + H]+, found 674.4564
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Glyco calcitroic methyl ester: To a solution of O-bis-silylated glyco
CTA methyl ester (49mg, 0.073mmol) in dry methanol (3.6mL)

NH
O
H

was added camphorsulfonic acid (102mg, 0.439mmol). The
reaction was monitored closely and quenched with NaHCO3 (2mL)
afte r 25 minutes. The reaction mixture was concentrated under

HO

OH

reduced pressure and the aqueous layer was extracted with DCM

(3x2mL). The combined organic layers were dried with MgSO4, concentrated, and purified by
column chromatography (MeOH : EtOAc 1:15) to yield glyco calcitroic methyl ester (25mg, 65%)
as a fluffy white powder; Rf 0.41 (EtOH: EtOAc 1:7); 1H-NMR (500MHz, CDCl3) δ 0.59 (s, 3H), 1.02
(d, J = 10.0 Hz, 3H), 1.27-1.41 (m, 3H), 1.43-1.60 (m, 3H), 1.63-1.72 (m, 2H), 1.72-1.83 (m, 3H),
1.83-2.04 (m, 6H), 2.32 (dd, J = 22.4, 10.8 Hz, 1H), 2.44 (d, J = 21.8 Hz, 1H), 2.60 (d, J = 22.0 Hz,
1H), 2.84 (d, J = 21.1 Hz, 1H), 3.77 (s, 3H), 4.06 (d, J = 8.1 Hz, 2H), 4.24 (s, 1H), 4.44 (s, 1H), 5.01
(s, 1H), 5.34 (s, 1H), 5.97-6.07 (m, 2H), 6.38 (d, J = 18.7 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ
12.1, 19.4, 22.3, 23.5, 27.7, 29.0, 34.4, 40.4, 41.2, 42.9, 43.6, 45.3, 46.0, 52.4, 56.3, 56.6, 66.8,
70.8, 111.8, 117.3, 124.8, 133.2, 142.7, 147.7, 170.6, 173.0; m/z calculated for C26H39NO5
446.2901 [M + H]+, found 446.2851; [𝛼]25
𝐷 = —4.0 (c 1.0, CHCl3)
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Glyco calcitroic acid: To a stirred solution of glyco CTA methyl
ester (20.2mg, 0.045mmol) in a minimum of MeOH (0.9mL) was

NH
O
H

added 1.8 mL of 15% w/v NaOH in H2O. The reaction was
completed in 10 minutes. Methanol was removed under reduced
pressure and the reaction mixture was dissolved in a minimum of

HO

OH

water. The reaction mixture was acidified and precipitated with

concentrated HCl to pH 2, then centrifuged and the precipitate collected by decanting the
supernatant and drying the remaining solid under reduced pressure. The crude solid was
desalted and purified using 500mg Sep-Pak Vac 6cc C18 cartridges (50% methanol/water) to
yield an off-white solid (7.3mg, 39%): Rf 0.53 (MeOH : EtOAc 3:2); 1H-NMR (500MHz, D2O) δ 0.50
(s, 3H), 0.89 (d, J = 6.45, 3H), 1.20-1.35 (m, 3H), 1.35-1.55 (m, 4H), 1.58-1.68 (m, 2H), 1.74-1.97
(m, 6H), 1.97-2.03 (m, 1H), 2.23 (dd, J = 13.1, 7.5 Hz, 1H), 2.40 (dd, J = 13.8, 3.6 Hz, 1H), 2.502.55 (m, 1H), 2.76-2.82 (m, 1H), 3.75 (dd, J = 27.0, 17.5 Hz, 2H), 4.07-4.12 (m, 1H), 4.34-4.37 (m,
1H), 4.94 (s, 1H), 5.25 (s, 1H), 6.01 (d, J = 11.3 Hz, 1H), 6.41 (d, J = 11.3 Hz, 1H); 13C-NMR:
(125MHz, MeOD) δ 11.2, 18.6, 19.3, 22.0, 23.2, 27.4, 28.6, 34.2, 40.5, 42.9, 43.0, 43.6, 45.2,
45.7, 56.3, 65.9, 70.0, 110.4, 118.0, 123.0, 135.5, 140.2, 149.3, 174.2, 175.9; m/z calculated for
C25H37NO5 432.2744 [M + H]+, found 432.2680; [𝛼]25
𝐷 = + 24.0 (c 1.0, MeOH)
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Bis-sulfo calcitroic acid: A solution of H2SO4 (160μL) and acetic
OH
O

minutes. When everything was solubilized, a solution of CTA

H

-

O
O

O

O
S

O

O

anhydride (280μL) was stirred in pyridine at 55°C for 5

S

-

(43.1mg, 0.115mmol) was added. The solution was stirred for

O
O

approximately ten minutes while monitoring by TLC, then

removed from heat and cooled to 0°C. To the cooled solution was added 25% aqueous NH4OH
(840μL). The solution was stirred for 5 minutes, filtered over a pad of celite followed by
evaporation. The crude residue was then loaded on an SPE cartridge, washed with water,
purified in a gradient up to 30% methanol in water, and then concentrated to the bis-sulfated
CTA as a white powder (18.4mg, 30.0%); Rf 0.18 (MeOH : EtOAc 3:7); 1H-NMR (500MHz, CDCl3) δ
0.63 (s, 3H), 1.04 (d, J = 6.2 Hz, 3H), 1.32-1.41 (m, 3H), 1.45-1.52 (m, 1H), 1.54-1.63 (m, 2H),
1.66-1.74 (m, 2H), 1.88-1.96 (m, 3H), 2.01-2.08 (m, 3H), 2.22-2.29 (m, 1H), 2.30-2.36 (m, 1H),
2.42-2.48 (m, 1H), 2.57 (dd, J = 13.7, 6.7 Hz, 1H), 2.67-2.72 (m, 1H), 2.85-2.91 (m, 1H), 4.77-4.83
(m, 1H), 5.00-5.06 (m, 2H), 5.47-5.50 (m, 1H), 6.12 (d, J = 11.1 Hz, 1H), 6.38 (d, J = 11.1 Hz, 1H);
13C-NMR:

(125MHz, CDCl3) δ 11.0, 18.7, 21.8, 23.2, 27.2, 28.6, 33.8, 36.6, 40.3, 41.0, 41.9, 45.6,

56.2, 56.3, 73.9, 76.7, 113.2, 117.7, 124.5, 132.8, 141.6, 143.7, 176.0; m/z calculated 533.1532
[M]— and 266.0783 [M]2—, found 533.1426 and 266.0674; [𝛼]25
𝐷 = —18.0 (c 1.0, MeOH)
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Mono-sulfo calcitroic acid: A solution of H2SO4 (0.5M) and
OH
O
H

solution of CTA (19.8mg, 0.053mmol) in pyridine (0.5mL) at
room temperature was added 105.7μL of the prepared

-

O

O S O
O

acetic anhydride (1M) in pyridine was prepared. To a stirred

OH

solution (0.053mmol H2SO4; 0.106mmol acetic anhydride).

The reaction was monitored for a half hour and quenched with 25% aqueous NH4OH (200μL).
The solution was stirred for 5 minutes and concentrated. The crude residue was then loaded on
an SPE cartridge, washed with water, purified in a gradient up to 60% methanol in water, and
concentrated to a clear oil (8.99mg, 37.5%); Rf 0.47 (MeOH : EtOAc 3 : 7); 1H-NMR (500MHz,
CDCl3) δ 0.64 (s, 3H), 1.04 (d, J = 6.2 Hz, 3H), 1.30-1.42 (m, 3H), 1.43-1.64 (m, 4H), 1.66-1.75 (m,
2H), 1.82-2.00 (m, 5H), 2.02-2.09 (m, 2H), 2.29-2.36 (m, 1H), 2.43-2.48 (m, 1H), 2.55-2.66 (m,
2H), 2.86-2.91 (m, 1H), 4.34-4.39 (m, 1H), 4.79-4.84 (m, 1H), 4.92-4.95 (m, 1H), 5.34-5.38 (m,
1H), 6.10 (d, J = 11.2 Hz, 1H), 6.34 (d, J = 11.2 Hz, 1H); 13C-NMR: (125MHz, CDCl3) δ 10.9, 18.7,
21.9, 23.2, 27.3, 28.5, 33.9, 40.3, 40.4, 41.0, 41.5, 41.9, 45.6, 56.1, 56.2, 68.8, 74.3, 109.6, 117.6,
123.6, 133.9, 141.0, 148.5, 176.1; m/z calculated 453.1958 [M]— , found 453.1867; [𝛼]25
𝐷 =—
18.0 (c 1.0, MeOH)
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1.11 A Brief Biological Characterization of Calcitroic Acid Conjugates

The four conjugates of CTA, which were synthesized using the methods described in
Chapter 1.10, were evaluated with different biochemical assays to determine their biological
activity. We used fluorescence polarization to determine the binding of these compounds
towards VDR and a transcription assay with HEK293 kidney cells to determine if these conjugates
modulate the transcription of P450 enzyme CYP24A1. Furthermore, we treated macrophages
(RAW264.7) with the CTA conjugated to determine possible anti-inflammatory properties.
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Binding to VDR using fluorescence polarization
Using the same method described in Chapter 1.7, recombinant VDR-LBD was incubated
in the presence of fluorescently labeled SRC2-3 peptide VDR agonist LG190178 and increasing
concentrations of CTA conjugates and calcioic acid. As shown in Figure 32, calcioic acid disrupts
the interaction between the agonist and VDR with an IC50 of 71μM. All CTA conjugates were able
to compete with LG190178, albeit with IC50 values higher than 92μM.

Figure 32: Binding curves for conjugates by FP analysis. EC50 values: calcioic
acid (71 ± 4 μM), CTA taurine (145 ± 25 μM), CTA glycine (92 ± 17 μM), CTA
mono sulfate (92 ± 5 μM), CTA bis sulfate (139 ± 20 μM).

Interaction with VDR using a transcription assay
Using the same method described in Chapter 1.7, HEK293T cells were transfected with
CMV-VDR plasmid for overexpression of VDR and the reporter plasmid of a luciferase gene under
the control of a CYP24A1 promoter. In the presence of VDR agonists, induction of the luciferase
gene occurs. This produces luciferase, which in the presence of luciferin substrate generates a
proportional bioluminescence signal. As shown in Figure 33, CTA glycine was the only CTA
110

conjugate that exhibited an agonist behavior with an EC50 of 49μM for the measured
concentration range. Calcioic acid was not able to induce VDR-mediated transcription but rather
showed some antagonistic behavior.

Figure 33: Transcription activation of CTA and its conjugates and
related compounds, shown as percentages of full calcitriol activation
at 60nM. EC50 of CTA taurine is 49 ± 21 μM.

Effect of CTA conjugates on macrophages
Using a Griess assay, the released NO concentration from activated RAW264.7 cells was
measured in the presence of CTA conjugates. This assay was introduced in Chapter 1.7 and the
results are summarized in Figure 34. Interestingly, all of the CTA conjugates and calcioic acid
showed a significant reduction of nitric oxide production at 12.5μM (Figure 34A). Positive control
compound dexamethasone at 100nM showed a similar effect. The reduction of NO in the
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presence of 25μM and 50μM CTA glycine was the most pronounced among all other CTA
conjugates (Figure 34B&C).
A

B

C

Figure 34: Significant deviation from stimulated macrophage (DMSO-treated) NO production seen at 12.5μM, with trends
increasing in significance at higher concentrations

In parallel, we investigated a possible toxic effect that could lead to a reduction of NO
production. Therefore, we determined the viability of these macrophages under the same
condition using Cell-Titer Glo. The results are summarized in Figure 35. For CTA conjugate
concentrations of up to a 100μM, no reduction of cell viability was observed.

Figure 35: Toxicity assay for macrophages. No toxicity was seen up to 100μM for
any of the compounds
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Discussion
Based on the defined VDR binding pocket for VDR agonists that was elucidated by X-ray
crystallography, it was not anticipated that any of the CTA conjugates would interact with VDR or
induce a VDR-mediated effects even at very high concentrations. Our results however confirmed
that these compounds at concentrations of 60μM and higher can interact with VDR. CTA glycine
was the only CTA conjugate showing an agonistic VDR-mediated effect at concentrations of
15μM and higher. Furthermore, we confirmed with the agonistic effect of CTA glycine that this
compound is cell-membrane permeable.
The CTA-related compound calcioic acid, however, was expected to bind to VDR, albeit at
higher concentrations than CTA because of its missing 1α-hydroxyl group. We were able to
confirm this hypothesis. However, the interaction between calcioic acid and VDR did not result in
any appreciable induction of transcription at a concentration of 100μM.
When macrophages were treated with CTA conjugates, a decrease in nitric oxide
production at 12.5μM and greater concentrations was observed. While no cell death was
apparent by our Cell-Titer Glow viability assay at any concentration, the possibility exists that
general protein production was compromised at these high concentrations of CTA conjugates
that in turn reduced the formation of NO. The only evidence that the reduction of NO formation
is linked to VDR in this study is the behavior of CTA glycine that showed activation of VDRmediated transcription and a very pronounced reduction of NO production. Similar effects were
described for CTA before. Assessing the toxicity of these conjugates using other metrics than ATP
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quantification (Cell-Titer Glo) will be carried out in the future to further investigate the antiinflammatory effect of vitamin D metabolites.
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Experimental Procedures:
Fluorescence Polarization Binding Assay Protocol
The FP assay buffer was prepared by adding 25mM PIPES (piperazine-N,N’-bis(ethanesulfonic
acid, Sigma-Aldrich), 50mM NaCl (Fisher), and 0.01% NP-40 detergent to 18.2MΩ water. The
buffer was filtered and adjusted to pH 6.75. To this was added 7.5nM of the coactivator peptide
SRC2-3 (CKKKENALLRYLLDKDDTKD) which had been labeled with cysteine-reactive AlexaFluor647.
To this solution was added 500nM of VDR-LBD, which had been expressed and purified as
reported previously.120 The VDR agonist LG190178, which had been synthesized previously
according to a published protocol,121-122 was added at a concentration of 600nM. A 20mM stock
of each CTA conjugate in DMSO was serially diluted (1:2) in a 384-well plate (Corning, CLS3702).
To a 384-well black polystyrene microplate (Corning, CLS3658), 20μL of the prepared VDR-LBD
assay solution was dispensed to test against the CTA conjugates’ serial dilution. Using the Tecan
Freedom EVO liquid handler system and a 100nL pin tool (V&P Scientific), a total of 100nL of
each CTA conjugate concentration was transferred in quadruplicate to the 20μL assay solution for
a final maximum concentration of 100μM of each conjugate. Following incubation for 1 hour,
fluorescence polarization was detected at an excitation/emission wavelength of 635/685 nm
using the Tecan Infinite M1000 plate reader.
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Transcription Assay Protocol
Human embryonic kidney (HEK293, ATCC CRL-3249) T cells were cultured in DMEM/High
Glucose (Hyclone, #SH3024301) with non-essential amino acids (Hyclone, #SH30238.01), 10 mM
HEPES (Hyclone, #SH302237.01), 5 x 106 units of penicillin and streptomycin (Hyclone,
#SV30010), and 10% of FBS (Gibco, #10082147). Transfection was carried out with 70-80%
confluent cells. For VDR transfection, 2 mL of untreated DMEM/High Glucose media containing
0.7 μg of VDR-CMV plasmid, 16 μg of a CYP24A1-luciferase reporter gene, LipofectamineTM LTX
(75 μl, Life Technologies #15338020), and PLUSTM reagent (25 μl) was added to the flask. After
16 hours of incubation at 37oC with 5% CO2, the cells were harvested with 3mL of 0.05% Trypsin
(Hyclone, #SH3023601), added to 10mL of the assay buffer (DMEM/High Modified buffer
without phenol red, Hyclone #SH30284.01) and spun down for 2 minutes at 1000 rpm. The
media was removed and cells were resuspended in the DMEM assay media. Prior to adding cells
to sterile white, optical bottom 384-well plates, plates were treated with 20 μL per well of a
0.25% matrigel solution. To each well, 20μL of cells were added to yield a final concentration of
15,000 cells per well. The plates were then spun down for 2 minutes at 1000 rpm. After four
hours, plated cells were treated with 100 nL of compounds and controls which were added using
the EVO liquid handling system with a 100nL pin tool (V&P Scientific). Controls used with VDR
were 1,25(OH)2D3 (10 nM in DMSO, Endotherm) and DMSO. After 16 hours of incubation at 37oC
with 5% CO2, 20μL of Bright-Glo™ Luciferase Assay Kit (transcription assay, Promega, Madison,
WI) were added and luminescence was read on the Tecan Infinite M1000 reader.
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Griess Assay Immune Modulation Protocol
The murine macrophage cancer cell line RAW264.7 was cultured in DMEM (ATCC 30-2002) with
10% FBS. To initiate an immune response, cells were suspended at a cell density of 1x10 6
cells/mL and a control sample (80μL x 8) was dispensed into a 384-well clear-bottomed sterile
plate with a lid (Nunc 142762). The remaining suspended cells were then activated with
interferon gamma (IFNγ, 150units/mL) and lipopolysaccharide (LPS, 50ng/mL). Activated cells
were dispensed into a 384-well plate (80μL/well). A dose-response 384-well plate (highest
concentration each: 100mM) of the compounds of interest was then used to dose the activated
cell plate with 100 nL using the EVO liquid handling system with a 100nL pin tool (V&P Scientific)
for a final highest concentration in the assay plate of 100μM. Each concentration was tested in
quadruplicate. The following controls were also dosed in octuplicate: activated cells with only
DMSO, dexamethasone (1μM), and the toxic compound CBT (10μM). The dosed cells were then
allowed to incubate for 24 hours.
Following incubation, aliquots of supernatant (40μL) from each well were moved to a separate
384-well clear-bottomed plate with a lid (CLS3700). To each aliquot was added 40μL of
sulfanilamide solution (Promega Griess Reagent System, TB229). The covered plate was shaken
briefly and incubated in the dark for 10 minutes. Following this, 40μL of NED solution (Promega
Griess Reagent System, TB229) was added to each aliquot. The plate was incubated in the dark
for 10 minutes. The absorbance of the plate was then read on the Tecan Infinite M1000 plate
reader (530nm).
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To the remaining 40μL of dosed cells and media was added 40μL of Cell Titer Glow luminescent
cell viability assay (Promega, G7572). The plate was shaken for 20 minutes and the luminescence
then read on the Tecan Infiniate M1000 plate reader.
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PART II: TOWARD THE DEVELOPMENT OF A NOVEL ORALLY-AVAILABLE ASTHMA
TREATMENT TARGETING GABAA RECEPTORS IN THE LUNGS
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2.1 A Brief Introduction to Asthma

The treatment and control of asthma remains a persistent modern clinical problem,
despite being recognized for decades and occurring all across the globe.10 An estimated 300
million people have asthma worldwide, including nearly 40 million in the United States.14 Its
prevalence is expected to continue to rise. The central hallmarks of asthma are chronically
inflamed airways, hypersensitivity to certain external stimuli, and obstruction of the airways.11
These characteristics lead to clinical features that include persistent cough, shortness of breath,
wheezing, coughing, and chest tightness.12
As a long-term disease affecting both children and adults, solutions for effective
treatment remain limited. The first line of chronic therapy is based on long-acting β2 adrenergic
receptor agonists with or without anti-inflammatory corticosteroids delivered with an inhaler.14
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Some cases of chronic asthma are able to be controlled using this method, and it does have the
advantage of providing a targeted delivery to the bronchial submucosa, thus avoiding the
systemic effects of corticosteroids delivered orally.151 However, the expected disadvantages due
to imprecise dosing and poor compliance are ubiquitous, and sometimes lead to loss of control
over the asthmatic symptoms.151 In more severe cases, asthmatic symptoms are treated
systemically with corticosteroids. These treatments can cause adverse side effects that include
growth suppression, thinning of the skin or excessive bruising, formation of cataracts, adrenal
suppression, and increased mortality.15-19 An alternative oral treatment exists in the form of a
leukotriene receptor antagonist (Montelukast) for those who do not respond well to other
methods;152 however, this treatment has a low success rate (somewhere between 35% and 78%
of patients do not respond to it).153 It is believed that genetic variations in leukotriene signaling
are responsible for this alternative therapy being inefficacious.153 A final treatment option is
injectable biological treatments such as the mlgE-expressing B lymphocyte-specific monoclonal
antibody omalizumab,154 or the interleukin-5-specific monoclonal antibody mepolizumab for
eosinophilic asthma.155 However, with patient costs for such treatments up to $30,000 a year
and the risk for anaphylaxis up to 0.2% with omalizumab,154 the widespread use of these
treatments is limited to only the most severe cases.
Our laboratory, in collaboration with the Cook laboratory at UWM, is seeking an alternate
therapy to combat multiple symptoms associated with living with acute asthma.1, 13 There are
several factors upon which current treatments could be improved: (1) A better asthma drug
alternative should be orally administered to improve patient compliance and eliminate dosage
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irregularity. (2) Furthermore, unwanted central nervous system effects should be avoided at all
cost. (3) Finally, the alternative drug should alleviate a full range of asthma symptoms, such as
relaxing the smooth muscle constriction and decreasing inflammation in the airways, rendering
combination treatments obsolete.20
Central to achieving those goals is a new therapeutic target for asthma, which is the
family of gamma-aminobutyric acid A receptors (GABAAR). GABAARs are ligand-gated chloride ion
channels, whose primary function is to regulate intracellular chloride concentrations, especially
in neurons. The GABAARs consists of five subunits combined into a heteropentamer. A typical
GABAAR on neurons consists of two alpha, two beta, and one “other” subunit out of the 19
known subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ, ρ1−3).21 Recently, GABAARs have been identified on
airway smooth muscle cells, airway epithelia cells, and inflammatory cells.1, 24, 156-160 These cell
types contain α4 and α5 subunits.24 In recent decades, the Cook group has introduced subtypeselective GABAAR ligands based on the benzodiazepine scaffold.22 Further investigations have
shown that these ligands mediate distinct pharmacological properties including relaxation of
airway smooth muscle and anti-inflammation. Proof of concept that GABAAR ligands can alleviate
asthma symptoms was first shown with plant-based positive allosteric modulator honokiol by
Munroe et al.23 Our group has since developed imidazobenzodiazepine-based compounds that
target relevant GABAAR subtypes expressed in the lung with pronounced efficacy in several
asthmatic mouse models.1, 13, 20, 24 Achieving targeted asthmatic relief with oral medication and
thus eliminating the use of corticosteroids is seen as a huge step forward in asthma treatment.
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2.2 Mucin Volume Density as a Marker of Asthmatic Disease State

Embedded within the epithelial layer of the bronchi,
larger bronchioles, and trachea are goblet cells.161 Their role
is to maintain the protective mucus membrane, which they
do by secreting mucins: large glycoproteins consisting
mainly of carbohydrates (Figure 36).161 The bound

Figure 36: Goblet cells adopted from
https://www.histology.leeds.ac.uk

carbohydrates attract appreciable amounts of water, giving
the mucin layer a jelly-like consistency and allowing surfaces to stay well-lubricated. The
essential protective role that mucins play keeps the surfaces of the lungs clean, as it immobilizes
stimulants like dust particles and bacteria. The cilia of the epithelial cells covered by the mucins
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beat the secretions and direct contaminants up out of the lungs, while the goblet cells continue
to produce more mucins as needed to replenish the mucous membrane.161
In the asthmatic disease state, goblet cells are overrepresented.162 This can be due to the
caused by the goblet cells dividing too often, known as goblet cell hyperplasia, or by too many
epithelial cells differentiating into goblet cells, known as mucus metaplasia.163 Both processes
create too many mucins, and both are known to occur in asthma. This excess of secretions
causes a dense, thick mucus layer that cannot be thinned out or removed in the usual manner by
cilia movement or even by coughing. Combined with the other classical asthma symptoms such
as constriction of the airways, the danger of clogging airways increases leading to asthma
exacerbations.
The purpose of this study was therefore to observe mucus overproduction in the
epithelial layer of an asthmatic mouse model and monitor the effect of new asthma drug
candidates.

Experimental section
Male BALB/c mice were injected i.p. with 50 μg ovalbumin adsorbed with 2 mg aluminum
hydroxide (alum) in saline (0.9% NaCl) to sensitize them on day 0, 7, and 14 of a study. On days
23-27, the asthmatic model was induced by challenging those mice intranasally with 25 μl of a
0.4 mg/ml ovalbumin solution. Concurrently, mice in testing groups received an assigned dosage
of small molecule, positive control compounds (β-agonists or Montelukast) or vehicle only as
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negative control. The mice were then given a final administration of these compounds before
euthanasia on day 28 followed by collections of tissues and fluids.
For evaluating lung mucin volume density, a cannula was inserted into the trachea of the
deceased mouse. The lungs were inflated with phosphate buffered saline to keep the airways
from collapsing. The larger left lung was collected and put in 10% buffered formalin over night at
4°C, followed by washes with 70% ethanol and storage in 70% ethanol. The samples were send
to Wisconsin Children’s Hospital for embedding and sectioning in paraffin. The lungs were
sectioned as follows: held vertically, the lung was cut through the middle, side to side, so that
the main axial airway was exposed as a circular disk. The primary concern during this process was
that lungs could be mishandled or crushed so that the mucus layer dislocates. However, the
presence of mucus secreted by goblet cell hyperplasia was consistent within every population
surveyed. Two slides were made for every mouse lung that was collected (one utilized and one
as a “backup” in case the first had problems, detailed below).
The returned slides with lung sections were handled as follows:

Preparation of solutions:


Fluorescent Schiff reagent solution: 0.75 g acriflavin HCl, 150 mL distilled water, 1.5 g
sodium metabisulphite, and 1.5 mL of a 10M solution of HCl. The solution must be kept in
the dark for 48 hrs 4°C before use. It will still decompose and stain much less brightly
within a week, so small batches are recommended.
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1% periodic acid solution: 1 g periodic acid and 100 mL distilled water. This solution must
be made fresh every time slides are stained.



Acid alcohol solution: 70mL ethanol, 29mL distilled water, and 1mL 10M HCl



Canada balsam mounting media: 50:50 Canada balsam and methyl salicylate

Dewaxing and rehydration of slides:


Immersed in histoclear, 2x for 30 minutes;



Immersed in 100% ethanol, 2x for 5 minutes;



Immersed in 95% ethanol in water, 2x for 5 minutes;



Immersed in 80% and then 70% ethanol in water for 5 minutes;



Immersed in PBS, 2x for 5 minutes.

Staining and preservation of slides:


Slides were oxidized in 1% periodic acid for 10 minutes;



Slides were rinsed with DI water, 3x for 5 minutes;



Slides were stained with fluorescent Schiff’s reagent for 20 minutes;



Slides were rinsed with DI water, 3x for 5 minutes;



Slides were rinsed with acid alcohol, 2x for 5 minutes;



Slides were air-dried in the dark.
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A few microliters of Canada balsam mounting media was placed on the section and the
coverslip was tilted carefully over it in order to avoid trapping air bubbles and protect
from disturbing the tissue. After leaving overnight, fixing is complete. The slides were
then evaluated the following day to avoid loss of fluorescence.
Image collection: Using an EVOS inverted digital
fluorescence microscope (Thermo Fisher), the
slides were carefully observed. The main axial
airway forms a large unstained hole through the
center of each lung section. Using the green
fluorescent protein (GFP) filter, the epithelia of

Figure 37: Overlay of GFP and RFP filtered images of
ovalbumin sensitized and challenged mouse airway
epithelium

the axial airway was zoomed to 40X. The

circumference was inspected to find areas that exhibited cells that were cut cleanly (ex: without
many layers of epithelial cells apparent in the background, making the “surface” of the
epithelium appear thicker than it really is) and a basement membrane free of “wrinkles.” The
scale bar of 100 μm was displayed on each image for scaling purposes later. Images of these
smooth, clean areas were taken, at a rate of exactly 4 per slide, spaced as much as was allowable
around the axial airway. If four acceptable non-overlapping images were unable to be captured
in a single sample, the “backup” slide was used instead. There were no cases wherein both slides
failed to have four acceptable images taken.
Images were taken using the GFP and the RFP (red fluorescent protein) filters on the
same image, and the two were overlaid to form a single image that exhibits green epithelium
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and basement tissue and red mucus in goblet cells (Figure 37). These raw images were saved as
JPG files and carefully numbered and categorized for later processing.
Processing procedure: Following the instructions of V. Kim et al,163 the images were opened with
the ImageJ software. Images were resized (imageadjustsize) to 680w x 512h pixels. Next,
the “straight line tool” was used to draw a line equal to the distance between the two points on
the ends of the scale bar. This line then was used to scale the picture (analyze  set scale). The
distance in pixels is displayed, and the length and units (100 um respectively) were entered. Note
that once this scale is known, it can be entered directly into the “set scale” selection for future
images.
Next, the length of the basement membrane was measured. The ROI manager was
opened (analyzetoolsROI manager). The “straight line tool” was used to draw lines along the
basement membrane, hitting CTRL+D each time to make the line permanent (alternatively:
editdraw). After each segment is drawn, hitting
“T” adds it to the ROI manager (alternatively,
clicking Add(t) in the ROI Manager window) (see
Figure 38). When the basement membrane had
been fully outlined, “measure” was clicked in the
ROI Manager window. A new window pops up
containing multiple fields with quantities
concerning those lines. The “length” measurement
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Figure 38: Using ROI manager to quantify data
concerning drawn line segments in airway epithelium
image opened in ImageJ

is all that is needed, but it is easier to save the whole set than select just that piece of data. The
whole set was saved, again carefully naming each one to reflect the image it came from.
Next, the area of mucus was measured. Whatever measurements are in the ROI Manager
were deleted. Then using the “freehand selection tool,” the circumference of an area of mucus
was outlined. The tool automatically closes the area off if the beginning and ending of an area
are not perfectly overlapped. As with the length measurements, after each area was finished,
CTRL+D and “T” are hit to make the lines permanent and add them to the ROI Manager. Once all
mucus areas were outlined, “measure” was clicked in the ROI Manager and the window that
pops up with quantities concerning those areas was saved.
This process was repeated for every image, which is why saving and naming them
carefully is an essential part of this data collection. Once all quantities were acquired, they were
consolidated. For each lung section, an Excel file was made. In that Excel file, the four images and
their quantities were first separately considered. Columns for “Length,” “Total Length,” “Area,”
“Total Area,” and “Mucin Volume Density” were made. For each of the four images, the
measured “Lengths” from the saved length file were added to the “Length” column, and the
measured “Areas” from the saved area file were added to the “Area” column. The “Total Length”
and “Total Area” columns displayed the sum of those values (=SUM(x)). The “Mucin Volume
Density” column uses the following equation:
𝑡𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎
𝑡𝑜𝑡𝑎𝑙 𝑙𝑒𝑛𝑔𝑡ℎ

4

· 𝜋 = 𝑚𝑢𝑐𝑖𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
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Equation 1

which converts the measured values (area density and length, effectively) into volume density.
These quantities need to be separately evaluated for each image in each lung. The four Mucin
Volume Densities were then averaged into a separate column for Mucin Volume Density Average
(=AVERAGE(Mucin Volume Densities)). Secondary values of Mucin Volume Density Standard
Deviation (=STDEV(Mucin Volume Densities)) and Standard Error (Standard Deviation/(3^0.5))
were also calculated.
A

B

C

Figure 39: (a) Representative control: vehicle-only mouse airway epithelium; (b) Representative positive control/treatments:
ovalbumin sensitized and challenged mouse airway epithelium. Note that all mice tested with small molecules also had the
same appearance; (c) Representative negative control: the corticosteroid dexamethasone decreased mucin quantities.

Results
We have investigated the pharmacological effects of α4-selective GABAAR positive
modulator (XHE-III-74EE)164 in an ovalbumin sensitized and challenged (Ova S/C) murine model
of asthma that represents an acute allergic pulmonary inflammation model. The results were
published in 2016 and are summarized in Figure 40.24
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ovalbumin sensitized/challenged

**
***
Compound 1
(XHE-III-74EE)

Figure 40: Mucin volume densities of mouse lungs treated with compound 1. CTL: Non-challenged; vehicle (3 % DMSO, 20%
propylene glycol and 77% water) given i.p. twice a day for 5 days; Dexamethasone (Dex) 4 mg/kg/day i.p. (5 days); Cmpd1: 20
mg/kg b.i.d., i.p. for 5 days or 40 minutes before euthanasia; osmotic mini-pumps that release 20 mg/kg/day for 7 days. Data is
represented as mean ± SEM, n = 7. ANOVA repeated measured was used for statistical analysis; *, **, *** indicates p<0.05 with
reference to the vehicle injection/pumps mice.

Non-challenged mice treated with i.p. injection of vehicle twice a day for five days were
used to determine the baseline levels of mucus produced by the mouse lung. Sensitization and
challenge with ovalbumin, however, significantly increase in mucin volume density levels to
almost 20 nL/mm2. When Ova S/C mice were injected for five days with 4 mg/kg/day of
glucocorticoid dexamethasone, a significant reduction of the lung mucin volume density was
observed. By comparison, XHE-III-74EE, when administered i.p. twice a day for five days at 20
mg/kg neither increased nor decreased the mucin volume density. A single i.p. injection of XHEIII-74EE 40 minutes before euthanasia showed that acute dosage also had no effect on mucin
volume density. To study a continuous release model of XHE-III-74EE, mini-pumps were
deposited under the skin on the back of the animals. The continuous application of vehicle
resulted in a mucin volume density similar to that of the vehicle i.p. injection. The continuous
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release of XHE-III-74EE at 20 mg/kg/day similarly did not significantly increase or decrease the
mucin volume over a period of seven days.
In the same paper, Compound 2, an α5-selective GABAAR positive modulator (SH-053-2F’R-CH3) was also tested in the same Ova S/C murine asthmatic inflammation model. The results
are summarized in Figure 41.24

Ova S/C

***
Compound 2
(SH-053-2F’-R-CH3)

Figure 41: Mucin volume densities for Compound 2.1 CTL: non-challenged; vehicle gavage: vehicle (3 % DMSO, 20% propylene
glycol and 77% water) administered twice daily for 5 days by oral gavage; Cmpd 2 gavage: 100 mg/kg administered twice
daily for 5 days by oral gavage. Data is represented as mean ± SEM, n = 7. ANOVA repeated measured was used for statistical
analysis; *, **, *** indicates p<0.05 with reference to the vehicle gavage mice.

Non-challenged mice in this study were challenged with i.n. saline twice a day for five
days to determine the baseline levels of mucus produced by the mouse lung. Sensitization and
challenge with ovalbumin again produced a comparable increase in mucin volume density levels
to around 20 nL/mm2. SH-O53-2F’-R-CH3, when administered twice a day for five days at
100mg/kg neither increased nor decreased the mucin volume density.
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In the same publication, Compound 3, an α4-selective GABAAR positive modulator (XHEIII-74A) was also tested in the same Ova S/S murine asthmatic inflammation model. The results
are summarized in Figure 42.24

Ova S/C

***

Compound 3
(XHE-III-74A)

Figure 42: Mucin volume densities for Compound 3.1 CTL: non-challenged; vehicle injection: vehicle (3 % DMSO, 20%
propylene glycol and 77% water) administered i.p. twice daily for 5 days.; Cmpd 3 inj.: 20 mg/kg b.i.d., i.p. for 5 days or 40
minutes before euthanasia. Data is represented as mean ± SEM, n = 7. ANOVA repeated measured was used for statistical
analysis; *, **, *** indicates p<0.05 with reference to the vehicle injection mice.

Non-challenged mice treated with i.p. injection of vehicle twice a day for five days were
used to determine the baseline levels of mucus produced by the mouse lung. Sensitization and
challenge again produced the expected mucin volume density levels. Again, XHE-III-74A when
administered i.p. twice a day for five days at 20 mg/kg or when given as a single i.p. injection 40
minutes before euthanasia neither increased nor decreased the mucin volume density.
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Discussion
None of the asthma drug candidates produced a result that deviated significantly from
their respective ovalbumin sensitized and challenged positive control group. This was apparent
both by visual inspection of the images and by quantitation. However, dexamethasone was
effective at significantly reducing the mucus volume density.
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